var title_f32_42_33440="Flurbiprofen: Drug information";
var content_f32_42_33440=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flurbiprofen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12624493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12624494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/29/22995?source=see_link\">",
"       Flurbiprofen (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30008?source=see_link\">",
"       Flurbiprofen (systemic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8470 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33440=[""].join("\n");
var outline_f32_42_33440=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/29/22995?source=related_link\">",
"      Flurbiprofen (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30008?source=related_link\">",
"      Flurbiprofen (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_42_33441="Central L SC supra needle";
var content_f32_42_33441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Needle insertion for central venous catheter placement using the supraclavicular approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When using the supraclavicular approach for central venous catheter placement, it is important that the needle be oriented properly. It should lie 10 to 15 degrees below the coronal plane and oriented to bisect the angle between the clavicle and the sternocleidomastoid. The needle should not be inserted too deeply; the subclavian vein generally lies 1 to 1.5 cm deep to the insertion point.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33441=[""].join("\n");
var outline_f32_42_33441=null;
var title_f32_42_33442="Pancreaticojej variations AGA";
var content_f32_42_33442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Variations on pancreatojejunostomies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: American Gastroenterological Association (AGA) GTP slide set (2003), Pancreatic Disease. Authors: Gorelick F, Pandol S, Topazian M. Artist: Schoendorf J. Copyright &copy; 2003 American Gastroenterological Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33442=[""].join("\n");
var outline_f32_42_33442=null;
var title_f32_42_33443="Sweet syndrome bulla";
var content_f32_42_33443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sweet syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesiculation is present in this inflammatory plaque of Sweet syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33443=[""].join("\n");
var outline_f32_42_33443=null;
var title_f32_42_33444="Etiology of bacterial meningitis in children";
var content_f32_42_33444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Etiology of bacterial meningitis in 231 children from 20 pediatric emergency departments, United States 2001-2004",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 616px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"     <br>",
"      *",
"      <em>",
"       Citrobacter diversus",
"      </em>",
"      ,",
"      <em>",
"       Enterobacter cloacae",
"      </em>",
"      ,",
"      <em>",
"       Klebsiella",
"      </em>",
"      spp,",
"      <em>",
"       Pasteurella multocida",
"      </em>",
"      ,",
"      <em>",
"       Pseudomonas aeruginosa",
"      </em>",
"      ,",
"      <em>",
"       Salmonella",
"      </em>",
"      spp.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       <em>",
"        Listeria monocytogenes",
"       </em>",
"       (2 percent); group A streptococcus (2 percent),",
"       <em>",
"        Moraxella catarrhalis",
"       </em>",
"       (0.4 percent).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Nigrovic LE, Kuppermann N, Malley R. Children with bacterial meningitis presenting to the emergency department during the pneumococcal conjugate vaccine era. Acad Emerg Med 2008; 15:522.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33444=[""].join("\n");
var outline_f32_42_33444=null;
var title_f32_42_33445="Nail nevus child";
var content_f32_42_33445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Nevus of the nail matrix in a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33445=[""].join("\n");
var outline_f32_42_33445=null;
var title_f32_42_33446="Treatment of acute decompensated heart failure in acute coronary syndromes";
var content_f32_42_33446=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute decompensated heart failure in acute coronary syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33446/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33446/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33446/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33446/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33446/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33446/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33446/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/42/33446/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute decompensated heart failure (ADHF) often have coronary artery disease with or without an acute coronary syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33446/abstract/1\">",
"     1",
"    </a>",
"    ]. The acute onset of severe myocardial ischemia can lead to a sudden impairment in systolic and diastolic function, resulting in a decreased cardiac output, elevated filling pressures and the development of pulmonary edema. Flash pulmonary edema can result from myocardial ischemia with or without myocardial infarction.",
"   </p>",
"   <p>",
"    Specific considerations apply to treatment of ADHF in patients presenting with acute coronary syndromes (ACS). The recommendations presented here are generally in agreement with those published in the 2004 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    STEMI guidelines with 2007 focused update, the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    <span class=\"nowrap\">",
"     UA/NSTEMI",
"    </span>",
"    guideline and the 2009 focused update of the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    heart failure guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33446/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall management of acute coronary syndrome and acute MI (including fuller discussion of all therapies including anticoagulant and antiplatelet agents), cardiogenic shock in the setting of acute MI and general treatment of ADHF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of right ventricular MI which typically presents with hypotension and clear lungs is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=see_link\">",
"     \"Right ventricular myocardial infarction\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REVASCULARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent revascularization is a major component of therapy for patients presenting with STEMI, and is particularly important for those with HF. Early revascularization is indicated for patients presenting with unstable",
"    <span class=\"nowrap\">",
"     angina/non-ST",
"    </span>",
"    elevation myocardial infarction",
"    <span class=\"nowrap\">",
"     (UA/NSTEMI)",
"    </span>",
"    and HF. As recommended in the 2009 focused update of the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    HF guidelines, urgent cardiac catheterization and revascularization is reasonable when it is likely to prolong meaningful survival in patients with acute HF and known or suspected acute myocardial ischemia due to occlusive coronary disease, especially when there are signs and symptoms of systemic hypoperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33446/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary percutaneous coronary intervention (PCI) is recommended in patients with STEMI when it can be performed within 90 minutes of first medical contact [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33446/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. In addition, it is reasonable to promptly (within 30 minutes of arrival) transfer patients with STEMI with severe HF to facilities capable of rapid revascularization.",
"     </li>",
"     <li>",
"      Fibrinolytic therapy is recommended for patients with STEMI when timely primary PCI cannot be performed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33446/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. For patients who have received fibrinolytic therapy, a strategy of coronary angiography with intent to perform PCI (or emergency CABG) is recommended for certain patients including those with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cardiogenic shock who are &lt;75 years of age who are candidates for revascularization",
"     </li>",
"     <li>",
"      Severe HF",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary edema OR",
"     </li>",
"     <li>",
"      Hemodynamically compromising ventricular arrhythmias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A strategy of pharmacoinvasive therapy following fibrinolytics is reasonable for patients with STEMI with cardiogenic shock who are &ge;75 years of age and who are suitable candidates for revascularization or for patients with hemodynamic instability",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent ischemic symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A strategy of early coronary angiography with intent to perform revascularization is indicated in certain",
"      <span class=\"nowrap\">",
"       UA/NSTEMI",
"      </span>",
"      patients (without serious comorbidities or contraindications to such procedures) including those with the following (as well as others discussed separately):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Refractory or recurrent angina",
"     </li>",
"     <li>",
"      Signs or symptoms of HF or new or worsening mitral regurgitation",
"     </li>",
"     <li>",
"      Reduced left ventricular systolic function (LVEF &lt;40 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diuretic use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretic (low to intermediate dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"     torsemide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"     bumetanide",
"    </a>",
"    ) should be administered to treat pulmonary congestion if there is associated volume overload. However, caution is advised to avoid unnecessary or excessive diuresis since some patients are normovolemic, particularly those without prior LV dysfunction and those who have not received fluid loading.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Supplemental oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;As for treatment of ADHF generally, supplemental oxygen should be administered to patients MI with arterial oxygen desaturation and assisted ventilation should be provided as needed. It is reasonable to administer oxygen to all patients with MI during the first six hours after presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33446/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients requiring supplemental oxygen, we suggest initial therapies in the following order:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-rebreather face mask delivering high-flow percent oxygen.",
"     </li>",
"     <li>",
"      If respiratory distress, respiratory acidosis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypoxia persist, we suggest noninvasive positive pressure ventilation (NPPV) as the preferred initial modality of assisted ventilation as long as the patient does not have a contraindication (",
"      <a class=\"graphic graphic_table graphicRef60442 \" href=\"mobipreview.htm?16/54/17259\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach is supported by evidence from meta-analyses and randomized trials in patients with cardiogenic pulmonary edema indicating that NPPV decreases the need for intubation and improves respiratory parameters.",
"   </p>",
"   <p>",
"    In addition, a meta-analysis found that continuous positive airway pressure (CPAP) decreases in-hospital mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33446/abstract/6\">",
"     6",
"    </a>",
"    ]. This beneficial effect on mortality was greater in trials with higher proportions of patients with ischemia or MI. These issues and conflicting data on a possible impact on mortality are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link&amp;anchor=H16#H16\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\", section on 'Cardiogenic pulmonary edema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with respiratory failure who fail NPPV, or do not tolerate or have contraindications to NPPV (",
"      <a class=\"graphic graphic_table graphicRef60442 \" href=\"mobipreview.htm?16/54/17259\">",
"       table 1",
"      </a>",
"      ) should be intubated for conventional mechanical ventilation. In such patients, positive end-expiratory pressure is often useful to improve oxygenation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link\">",
"       \"Overview of mechanical ventilation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30663?source=see_link\">",
"       \"Positive end-expiratory pressure (PEEP)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once initial therapy has begun, oxygen supplementation can be titrated in order to keep the patient comfortable and arterial oxygen saturation above 90 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Morphine sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of STEMI,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine sulfate",
"    </a>",
"    is recommended as the analgesic of choice for ischemic pain relief provided that additional therapy is used to manage the underlying ischemia. In",
"    <span class=\"nowrap\">",
"     UA/NSTEMI,",
"    </span>",
"    it is reasonable to administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    if there is uncontrolled ischemic pain, provided that additional therapy is used to manage the underlying ischemia. The recommendation for morphine is less strong in",
"    <span class=\"nowrap\">",
"     UA/NSTEMI",
"    </span>",
"    as compared to STEMI because observational data has raised concern about excess mortality in",
"    <span class=\"nowrap\">",
"     UA/NSTEMI",
"    </span>",
"    patients receiving morphine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vasodilator therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     Nitroglycerin",
"    </a>",
"    is recommended for MI patients to treat ischemic pain, hypertension, or pulmonary congestion unless the systolic blood pressure is &lt;100 mmHg or &ge;30 mmHg below baseline.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     Nitroprusside",
"    </a>",
"    is often used when pronounced afterload reduction is required (as in the setting of ventricular septal rupture). However, limited data are available on the efficacy and safety of nitroprusside use in the setting of acute MI. One report suggested that nitroprusside administration after MI has an equivocal impact on mortality (worsening of mortality with early administration and improvement of mortality with later treatment) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33446/abstract/7\">",
"     7",
"    </a>",
"    ]. The adverse effect of nitroprusside in patients with acute MI may be attributable to reflex tachycardia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coronary steal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Beta blocker therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although initiation of beta-blocker therapy within the first 24 hours is generally recommended for patients presenting with MI, such therapy is contraindicated in patients with signs of HF, evidence of a low output state, increased risk of cardiogenic shock, or other contraindications such as heart block or reactive airways disease.",
"   </p>",
"   <p>",
"    Beta blocker therapy should be initiated before discharge for secondary prevention and continued indefinitely in all patients who have had an MI or ACS, unless contraindicated. For those who remain in HF throughout the hospitalization, low doses should be initiated, with gradual titration on an outpatient basis.",
"   </p>",
"   <p>",
"    Beta blocker therapy in patients with MI is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     ACE inhibitor and ARB therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of an oral angiotensin converting enzyme (ACE) inhibitor is recommended in patients with an acute MI who have heart failure or systolic dysfunction (left ventricular ejection fraction &le;40 percent) unless the systolic blood pressure is &lt;100 mmHg or &gt;30 mmHg below baseline or there are other contraindications. Therapy should be administered orally and titrated starting with a low initial dose. It should be noted that aggressive ACE inhibitor therapy prior to percutaneous intervention for AMI, or prior to hemodynamic stabilization has been associated with an increased risk of cardiogenic shock.",
"   </p>",
"   <p>",
"    ACE inhibitors should be initiated before discharge for secondary prevention and continued indefinitely in certain MI patients, including those with HF, LVEF&le;40 percent, hypertension, diabetes or chronic kidney disease.",
"   </p>",
"   <p>",
"    An angiotensin II receptor blocker (ARB) should be administered to MI patients with HF, LVEF &le;40, or hypertension who are intolerant of ACEI.",
"   </p>",
"   <p>",
"    ACE inhibitor or ARB therapy should continue indefinitely. Careful blood pressure monitoring is required when using either agent. ACE inhibitor and ARB use in MI patients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Aldosterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inpatient initiation of long-term aldosterone blockade (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) is recommended in post-MI patients with LVEF &le;40 and symptomatic HF",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diabetes without significant renal dysfunction (serum creatinine &le;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [221",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    in men and &le;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [177",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    in women) or hyperkalemia who are already receiving therapeutic doses of ACE inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/20/41289?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of acute myocardial infarction in diabetes mellitus\", section on 'Aldosterone antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF LOW OUTPUT STATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low output state may manifest as hypotension or preserved blood pressure with evidence of hypoperfusion and is not always accompanied by pulmonary congestion. Recommended treatments include inotropic support, intra-aortic counterpulsation, revascularization, and surgical correction of mechanical complications (such as ventricular septal rupture or papillary muscle rupture). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39225?source=see_link\">",
"     \"Mechanical complications of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Inotropic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MI, pulmonary congestion and marginal or low blood pressure often require circulatory support with inotropic and vasopressor agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intra-aortic balloon counterpulsation to relieve pulmonary congestion and maintain adequate perfusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    STEMI guidelines suggest using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    in hypotensive patients with clinical evidence of shock and using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    in hypotensive patients without clinical evidence of shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33446/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dopamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not mentioned in the 2006 HFSA ADHF guidelines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    is recommended for hypotensive STEMI patients with clinical evidence of shock in the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines. Its actions are complex and dose-dependent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At low doses of 1 to 3",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      acts primarily on dopamine-1 receptors to dilate the renal and mesenteric artery beds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33446/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At 3 to 10",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      also stimulates beta-1 adrenergic receptors and increases cardiac output, predominantly by increasing stroke volume with variable effects on heart rate.",
"     </li>",
"     <li>",
"      At medium-to-high doses,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      also stimulates alpha-adrenergic receptors, producing arterial and venous constriction that may compromise systolic function and filling pressures. However, a study of 13 patients with class III or IV chronic HF with severe LV systolic dysfunction suggested that renal arterial vasodilation and improvement in cardiac output may persist as the dopamine dose is titrated up to 10",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33446/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     Dopamine",
"    </a>",
"    should be reserved for hypotensive patients for whom an increase in arterial pressure is considered a priority.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Dobutamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    in ADHF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22359916\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with acute decompensated heart failure (ADHF) often have coronary artery disease with or without an acute coronary syndrome (ACS). Acute onset of myocardial ischemia with or without infarction can cause systolic or diastolic dysfunction resulting in decreased cardiac output, elevated filling pressures",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the development of pulmonary edema. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urgent revascularization is a major component of therapy for patients presenting with ST elevation myocardial infarction (STEMI), and is particularly important for those with heart failure (HF). Early revascularization is indicated for patients presenting with unstable",
"      <span class=\"nowrap\">",
"       angina/non-ST",
"      </span>",
"      elevation myocardial infarction",
"      <span class=\"nowrap\">",
"       (UA/NSTEMI)",
"      </span>",
"      and HF. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Revascularization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical therapy of ADHF with ACS includes judicious use of diuretics, supplemental oxygen and ventilatory support as needed, and vasodilator therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initiation of oral angiotensin converting enzyme (ACE) inhibitor is recommended within the first 24 hours of an acute MI in patients with pulmonary congestion or a left ventricular ejection fraction &le;40 percent. Beta blocker therapy within the first 24 hours is generally recommended for patients presenting with MI but initiation should be deferred in patients with HF. Inpatient initiation of long term aldosterone antagonist therapy is also recommended in selected patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Medical therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13175?source=see_link\">",
"       \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link\">",
"       \"Use of aldosterone antagonists in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with MI, pulmonary congestion and marginal or low blood pressure often require circulatory support with inotropic and vasopressor agents",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intra-aortic balloon counterpulsation to relieve pulmonary congestion and maintain adequate perfusion. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Management of low output states'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=see_link\">",
"       \"Intraaortic balloon pump counterpulsation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the setting of STEMI,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      is recommended in hypotensive patients with clinical evidence of shock and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      is recommended in hypotensive patients without clinical evidence of shock. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Inotropic agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33446/abstract/1\">",
"      Flaherty JD, Bax JJ, De Luca L, et al. Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol 2009; 53:254.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     Antman, E, Hand, M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. Available at: www.acc.org/qualityandscience/clinical/statements.htm (accessed May 2, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33446/abstract/4\">",
"      Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33446/abstract/5\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33446/abstract/6\">",
"      Weng CL, Zhao YT, Liu QH, et al. Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med 2010; 152:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33446/abstract/7\">",
"      Cohn JN, Franciosa JA, Francis GS, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med 1982; 306:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33446/abstract/8\">",
"      Elkayam U, Ng TM, Hatamizadeh P, et al. Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action. Circulation 2008; 117:200.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3498 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33446=[""].join("\n");
var outline_f32_42_33446=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22359916\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REVASCULARIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diuretic use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Supplemental oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Morphine sulfate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vasodilator therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Beta blocker therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ACE inhibitor and ARB therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Aldosterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT OF LOW OUTPUT STATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Inotropic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dopamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Dobutamine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22359916\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3498\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3498|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/54/17259\" title=\"table 1\">",
"      Contraindications to NPPV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=related_link\">",
"      Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30663?source=related_link\">",
"      Positive end-expiratory pressure (PEEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/20/41289?source=related_link\">",
"      Treatment of acute myocardial infarction in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_42_33447="Selection of sunscreen and sun-protective measures";
var content_f32_42_33447=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Selection of sunscreen and sun-protective measures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33447/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33447/contributors\">",
"     Elma D Baron, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33447/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33447/contributors\">",
"     Craig A Elmets, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33447/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33447/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/42/33447/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9546092\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sunlight is essential for synthesis of vitamin D and has beneficial effects on mood. However, ultraviolet (UV) radiation (290 to 400 nm (",
"    <a class=\"graphic graphic_figure graphicRef70045 \" href=\"mobipreview.htm?15/8/15502\">",
"     figure 1",
"    </a>",
"    )) is responsible for several acute and chronic detrimental effects on human skin, including sunburn, photoaging, and skin cancer.",
"   </p>",
"   <p>",
"    UVB (290 to 320&nbsp;nm), which represents only 5 percent of the UV reaching the earth surface, includes the biologically most active wavelengths. UVB is responsible for sunburn, inflammation, hyperpigmentation, and photocarcinogenesis.",
"   </p>",
"   <p>",
"    Approximately 95 percent of the UV radiation reaching the earth surface is UVA (320 to 400&nbsp;nm). UVA2 (320 to 340 nm), which constitutes approximately 25 percent of the UVA band, produces similar effects on the skin as UVB. UVA1 (340 to 400 nm) is less potent than UVA2 and has a decreased ability to induce erythema. UVA has a major role in photoaging and pigment darkening and may be involved in skin carcinogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Photoprotection, which includes sun avoidance during peak hours, sun-protective clothing, and sunscreens, is crucial to prevent or reduce the potential harms associated with UV exposure.",
"   </p>",
"   <p>",
"    Sunscreens and sun-protective clothing are reviewed here. Sunburns, photosensitivity disorders, and photoaging are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30136?source=see_link\">",
"     \"Sunburn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18426?source=see_link\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23400?source=see_link\">",
"     \"Photoaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9546099\">",
"    <span class=\"h1\">",
"     TYPES OF SUNSCREENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sunscreens are topical preparations containing filters that reflect or absorb radiation in the ultraviolet (UV) wavelength range (",
"    <a class=\"graphic graphic_figure graphicRef70045 \" href=\"mobipreview.htm?15/8/15502\">",
"     figure 1",
"    </a>",
"    ). In the United States, where sunscreens are considered to be over-the-counter drugs, 17 different UV filters are approved by the US Food and Drug Administration as active ingredients (",
"    <a class=\"graphic graphic_table graphicRef73127 \" href=\"mobipreview.htm?6/27/6589\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/4\">",
"     4",
"    </a>",
"    ]. Many other UV filters are available in Europe, Canada, and Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sunscreens are classified as organic (formerly known as chemical sunscreens) and inorganic (formerly known as physical sunscreens). Broad-spectrum sunscreens are generally combinations of sunscreen products that are able to absorb both UVB and UVA radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66298617\">",
"    <span class=\"h2\">",
"     Organic filters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organic filters (",
"    <a class=\"graphic graphic_table graphicRef73127 \" href=\"mobipreview.htm?6/27/6589\">",
"     table 1",
"    </a>",
"    ) include a variety of aromatic compounds that absorb UV radiation and convert it to a negligible amount of heat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/7\">",
"     7",
"    </a>",
"    ]. Some organic agents such as cinnamates and salicylates specifically absorb UVB. Among cinnamates, octinoxate is the most widely used UVB filter worldwide.",
"   </p>",
"   <p>",
"    Benzophenones provide UVB and short-wavelength UVA (UVA2) protection. Oxybenzone (benzophenone-3) is the most commonly used UVA filter worldwide. Avobenzone is an effective filter for long-wavelength UVA radiation (UVA1) but is extremely photolabile and needs to be stabilized with other compounds such as octocrylene, a weak UVB absorber.",
"   </p>",
"   <p>",
"    Broad-spectrum sunscreens are generally produced by combining filters with varying UV absorption spectra. As an example, avobenzone can be combined with UVB filters such as homosalate and octisalate to yield broad-spectrum coverage. A new generation of broad-spectrum organic filters has been developed in Europe, including methylene bis-benzotriazolyl tetramethylbutylphenol (Tinosorb M",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) and bis-ethylhexyloxyphenol methoxyphenol triazine (Tinosorb S",
"    <sup>",
"     &reg;",
"    </sup>",
"    ), terephthalylidene dicamphor sulfonic acid (Mexoryl&trade; SX), and drometrizol trisiloxane (Mexoryl&trade; XL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mexoryl SX and Mexoryl XL are photostable broad-spectrum agents absorbing UVB and short wavelength UVA (UVA2). Both prevent UV-induced pigmentation and show a synergistic effect when used in combination. Mexoryl XS has been available in the United States since 2006 in combination with avobenzone and octocrylene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25103687\">",
"    <span class=\"h2\">",
"     Inorganic filters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inorganic filters (",
"    <a class=\"graphic graphic_table graphicRef73127 \" href=\"mobipreview.htm?6/27/6589\">",
"     table 1",
"    </a>",
"    ) are mineral compounds such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    and titanium dioxide that are able to reflect and scatter UV light over a wide range of wavelengths. Micronized preparations can also absorb UV radiation. Inorganic sunscreens are stable, and in contrast to organic filters, have a low irritating and sensitizing potential. Inorganic sunscreens offer broad-spectrum protection against UVB, short-wavelength UVA (UVA2), and long-wavelength UVA (UVA1).",
"   </p>",
"   <p>",
"    Older inorganic sunscreens contained large size particles and formed a cosmetically unacceptable and occlusive white film on the skin. To overcome this cosmetic shortcoming, nanotechnology methods have been used to produce titanium dioxide or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    particles in the size range of 5 to 20 nm. Nanoparticle products form a more transparent film on the skin and provide effective UVA and UVB protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the utilization of titanium dioxide and zinc oxide nanoparticles into sunscreens has raised questions regarding possible alteration of their absorption spectrum and the potential for percutaneous penetration and toxicity. (See",
"    <a class=\"local\" href=\"#H9546127\">",
"     'Safety'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9424584\">",
"    <span class=\"h2\">",
"     Labeling and regulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sun protection factor (SPF) measures the sunscreen ability to protect against UVB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/10\">",
"     10",
"    </a>",
"    ]. SPF refers to the ratio, comparing sunscreened and non-sunscreened skin, of the minimal dose of solar radiation that produces perceptible erythema (minimal erythema dose, MED). The SPF is assessed in experimental conditions using a light source that simulates the solar radiation on the skin of light-skinned volunteers who have applied an amount of sunscreen corresponding to 2",
"    <span class=\"nowrap\">",
"     mg/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9424613\">",
"     'SPF'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The SPF does not adequately measure protection from UVA, which comprises 95 percent of the total UV radiation that reaches the earth at sea level. The lack of adequate information on the degree of UVA protection provided by sunscreens prompted the US Food and Drug Administration (FDA) to issue new regulations for labeling sunscreen products in 2011. Sunscreen manufacturers will have until December 2013 to comply [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Under the new regulations, only sunscreen products that pass the FDA&rsquo;s test for protection against both ultraviolet A (UVA) and ultraviolet B (UVB) rays will be labeled as &ldquo;broad spectrum.&rdquo; The UVA protection is not rated. Sunscreen products that meet the FDA&rsquo;s standards and contain a sun protection factor (SPF) of 15 or higher can be designated as sunscreens that decrease the risk of skin cancer and early skin aging caused by the sun when used as directed with other sun protection measures. The FDA also recommends that the SPF level be capped at 50 and that sunscreens with SPF &gt;50 be labeled as SPF = 50+.",
"   </p>",
"   <p>",
"    A 5-star rating system for UVA protection has been recommended to the industry by the European Union, where a number of UVA sunscreen agents (eg, Tinosorb M",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Tinosorb S",
"    <sup>",
"     &reg;",
"    </sup>",
"    , or Mexoryl&trade; XL), have been available for many years. The UVA protection level refers to the ratio of",
"    <span class=\"nowrap\">",
"     UVB/UVA",
"    </span>",
"    protection, and is required to be at least one third of the labeled SPF.",
"   </p>",
"   <p>",
"    The terms &ldquo;water resistant&rdquo; and &ldquo;very water-resistant&rdquo; mean that the SPF is maintained after 40 or 80 minutes of activity in water, respectively. The FDA no longer allows sunscreen products to be labeled &ldquo;sweat-proof&rdquo; or &ldquo;water-proof.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11208302\">",
"    <span class=\"h1\">",
"     WHO SHOULD USE SUNSCREEN?",
"    </span>",
"    &nbsp;&mdash;&nbsp;All individuals, regardless of skin phototype (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"mobipreview.htm?15/37/15963\">",
"     table 2",
"    </a>",
"    ), are subject to the potential adverse effects of UV radiation and will benefit from sunscreen use. However, sunscreens are especially useful for individuals with light skin (phototypes I, II, and III) who are more susceptible to the acute (sunburn) and chronic (photoaging, skin cancer) adverse effects of excessive sun exposure.",
"   </p>",
"   <p>",
"    Light skinned individuals should regularly use sunscreens with SPF 30 or higher when performing outdoor activities in sunny weather, especially in regions with high level of insolation. Although there is minimal increased effectiveness for sunscreens with SPF over 15 in experimental settings, individuals typically do not apply sunscreen in the recommended amount (approximately 1 ounce per total body application) and thus may benefit from a higher SPF. This is consistent with the recommendations of the",
"    <a class=\"external\" href=\"file://www.aad.org/media-resources/stats-and-facts/prevention-and-care/sunscreens\">",
"     American Academy of Dermatology",
"    </a>",
"    . &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9546106\">",
"    <span class=\"h1\">",
"     SELECTION OF SUNSCREEN PRODUCTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9424613\">",
"    <span class=\"h2\">",
"     SPF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between SPF and protection is not linear. Thus, SPF 30 sunscreens are not twice as protective as SPF 15. When applied in sufficient amount, the amount of UVB radiation absorbed by SPF 15, 30 and 50 sunscreen products is 93, 97, and 98 percent respectively. Products with SPF &gt;50 provide only a negligible increase in the protection from UV.",
"   </p>",
"   <p>",
"    Sunscreen products with SPF 15 are generally recommended for daily use. Sunscreen-containing cosmetics (eg, facial moisturizers, foundations) may improve photoprotection compliance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/15\">",
"     15",
"    </a>",
"    ]. Most cosmetic products are formulated to provide a SPF of 15 to 30 and may or may not be labeled as broad spectrum. Cosmetics providing broad spectrum protection should be preferred to those containing only UVB filters.",
"   </p>",
"   <p>",
"    Sunscreen products with SPF 30 or higher are recommended for individuals performing outdoor work, sports, or recreational activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9424629\">",
"    <span class=\"h2\">",
"     Spectrum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Broad spectrum sunscreens that offer sufficient protection against UVB, UVA2, and UVA1 are preferred to products containing only UVB filters, since both UVA and UVB are involved in skin photoaging and photocarcinogenesis. Although most UVB filters, particularly those with a high SPF, provide some protection against UVA2 radiation, the only three ingredients that satisfy the definition of UVA1 protection are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avobenzone (organic)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"       Zinc oxide",
"      </a>",
"      (inorganic)",
"     </li>",
"     <li>",
"      Titanium dioxide (inorganic)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Avobenzone is typically combined with UVA2 and UVB organic filters (eg, cinnamates, benzophenones, or octocrylene) or inorganic filters to achieve broad spectrum protection and photostability (",
"    <a class=\"graphic graphic_table graphicRef73127 \" href=\"mobipreview.htm?6/27/6589\">",
"     table 1",
"    </a>",
"    ). Sunscreens containing only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    titanium dioxide in adequate concentration provide protection against the entire UV spectrum. However, inorganic filters are often combined with organic filters to maximize efficacy and cosmetic acceptability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9424637\">",
"    <span class=\"h2\">",
"     Formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research has focused on the development of cosmetically appealing sunscreens that ensure compliance. A common reason for noncompliance is the stickiness of the product, which is greater with higher SPF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since sunscreen ingredients are oil-soluble, the most widely commercialized sunscreen products (eg, lotions and creams) are oil-in-water emulsions, in which microscopic drops of oily materials are dispersed in a continuous water phase that typically contains also other polar ingredients like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    or glycols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/17\">",
"     17",
"    </a>",
"    ]. Lotions are thinner and less greasy than creams and are generally preferred for application over large body areas.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Ethanol/oil-based",
"    </span>",
"    products in combination with polymeric thickeners are used to manufacture liquid, spray, or gel sunscreens. These formulations are fast-drying and leave a cooling sensation on the skin due to their quick evaporation, but may be irritating. Gels and sprays are preferred by patients with acne or by individuals who work or perform sports activities outdoors in hot weather. However, ethanol-based sunscreens may leave an uneven product film on the skin after evaporation, providing an inconsistent SPF performance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9546113\">",
"    <span class=\"h1\">",
"     PROPER USE OF SUNSCREENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sunscreens must be applied liberally, repeatedly, and to all sun-exposed parts of the skin to provide effective protection. To achieve the full SPF value on the product label, the amount (2",
"    <span class=\"nowrap\">",
"     mg/cm",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    of sunscreen necessary to cover sun exposed skin of an average-sized adult when on a beach vacation is equivalent of the amount required to fill a 1 ounce (30 ml) shot glass. Most people do not apply such a large amount [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/18\">",
"     18",
"    </a>",
"    ]. Therefore, SPF 30 or greater sunscreens should be recommended to compensate.",
"   </p>",
"   <p>",
"    Timing of application is important. Sunscreens should be applied 15 to 30 minutes before sun exposure to allow the formation of a protective film on the skin. Reapplication at least every two hours is necessary. Because all sunscreens are washed off upon swimming or sweating, reapplication after each water exposure (swimming) is needed even for sunscreen products labeled as &ldquo;water-resistant&rdquo; or &ldquo;very water-resistant&rdquo;. (See",
"    <a class=\"local\" href=\"#H9424584\">",
"     'Labeling and regulations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9546120\">",
"    <span class=\"h1\">",
"     BENEFITS OF SUNSCREENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9424682\">",
"    <span class=\"h2\">",
"     Skin cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is strong evidence that sunscreens prevent the development of actinic keratoses and squamous cell carcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. A follow-up study of a community-based, randomized trial in Queensland, Australia, found that the regular use of sunscreen reduces the incidence of melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/22\">",
"     22",
"    </a>",
"    ]. The extent to which the use of sunscreens reduces the incidence of basal cell carcinoma is uncertain. The studies that have been published have shown a reduction in basal cell carcinoma incidence, but it has not been statistically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30968?source=see_link&amp;anchor=H3202061#H3202061\">",
"     \"Treatment of actinic keratosis\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=see_link&amp;anchor=H28#H28\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18073?source=see_link&amp;anchor=H49281224#H49281224\">",
"     \"Primary prevention of melanoma\", section on 'Sunscreen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9424696\">",
"    <span class=\"h2\">",
"     Photoaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sunscreen may prevent skin changes such as pigmentation and wrinkling that are attributable to chronic photodamage or photoaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23400?source=see_link&amp;anchor=H16665039#H16665039\">",
"     \"Photoaging\", section on 'Photoprotection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9424717\">",
"    <span class=\"h2\">",
"     Photodermatoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Broad spectrum sunscreens with high SPF are generally used for the prevention of photodermatoses, which can be elicited by either UVB or UVA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18426?source=see_link\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A small study including patients with polymorphous light eruption found that a sunscreen with high SPF and high UVA protection factor containing photostable UV filters (Tinosorb&reg; M and Tinosorb&reg; S) and photostabilized avobenzone prevented the development of lesions after standardized photoprovocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9546127\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11208628\">",
"    <span class=\"h2\">",
"     Systemic absorption and toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current evidence suggests that most sunscreens have an excellent safety profile and are without significant systemic absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/25\">",
"     25",
"    </a>",
"    ]. However, the integration of titanium dioxide and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    nanoparticles into sunscreens has raised questions regarding their potential percutaneous penetration and toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/22,26\">",
"     22,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro studies have indicated that nanoparticles of titanium dioxide may induce the generation of reactive oxygen species with and without UV irradiation, which is the proposed mechanism for its possible toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/10,27,28\">",
"     10,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some in vivo and in vitro studies, however, have provided evidence that nanoparticulate titanium dioxide and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    do not penetrate beyond the stratum corneum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/11,12,29\">",
"     11,12,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2009, a review of studies on the use of nanoparticulate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    and titanium dioxide in sunscreens was performed by the Australian Government Therapeutic Goods Administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/30\">",
"     30",
"    </a>",
"    ]. The review concluded that titanium dioxide and zinc oxide nanoparticles do not reach viable skin cells, but they remain in the outer layer of the skin (stratum corneum) that is composed of non-viable cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11208635\">",
"    <span class=\"h2\">",
"     Irritant and allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse reactions from sunscreen ingredients have been reported and include allergic and irritant contact dermatitis, phototoxic and photoallergic reactions, contact urticaria, and rare anaphylactic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/18,31\">",
"     18,31",
"    </a>",
"    ]. Most of the UV filters known to be contact sensitizers such as PABA, amyl-dimethyl-PABA, or benzophenone-10, are now rarely used in sunscreen manufacture.",
"   </p>",
"   <p>",
"    Oxybenzone (benzophenone-3), the most widely used UVA filter worldwide, is the most frequent cause of sunscreen-induced photoallergic contact dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/31\">",
"     31",
"    </a>",
"    ]. However, the estimated rate of contact sensitization to oxybenzone containing products is &lt;0.1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11208664\">",
"    <span class=\"h2\">",
"     Hormonal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some UV filters (eg, octinoxate or oxybenzone) have been found to have estrogenic effects in vitro or in animal models. In one study, oral oxybenzone induced an uterotrophic effect in immature rats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/33\">",
"     33",
"    </a>",
"    ]. However, hormonal effects of UV filters from percutaneous absorption have not been reported in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/27\">",
"     27",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4593870\">",
"    <span class=\"h1\">",
"     SUNSCREENS AND VITAMIN D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since sun exposure is necessary for the synthesis of 25-hydroxyvitamin D in the skin, there has been concern that photoprotective measures could result in vitamin D deficiency. There is no evidence from randomized trials or longitudinal studies in real-life scenarios that sunscreen use significantly suppresses cutaneous vitamin D production. In experimental settings, the production of vitamin D appears to be greatly reduced by the application of adequate amounts of sunscreen before UVB exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/34-37\">",
"     34-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who need to adopt strict photoprotective measures, oral vitamin D supplementation is a safe, well-tolerated, and inexpensive alternative to sun exposure to achieve adequate vitamin D levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28266?source=see_link\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9546134\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL EFFECTS OF SUNSCREENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UV filters are potential environmental contaminants because they are measurable in many aquatic ecosystems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/39\">",
"     39",
"    </a>",
"    ]. Direct effects of sunscreen run-off on coral reefs are limited, although in vitro studies have shown that some UV filters are capable of disrupting the ecological balance in corals resulting in their bleaching [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9546141\">",
"    <span class=\"h1\">",
"     PHOTOPROTECTIVE CLOTHING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wearing clothes is important for sun protection. The degree of protection provided by clothes is defined by the ultraviolet protection factor (UPF), which indicates how effective a fabric is at blocking out solar ultraviolet radiation. The Australian Radiation Protection and Nuclear Safety Agency introduced a standardized UPF testing method for fabrics in 1996 and established rules for appropriate labeling of clothes claiming to offer sun protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that contribute to the UPF rating of a fabric are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Composition of the yarns (cotton, polyester, etc)",
"     </li>",
"     <li>",
"      Tightness of the weave or knit (tighter improves the rating)",
"     </li>",
"     <li>",
"      Color (darker colors are generally better)",
"     </li>",
"     <li>",
"      Stretch (more stretch lowers the rating)",
"     </li>",
"     <li>",
"      Moisture (many fabrics have lower ratings when wet)",
"     </li>",
"     <li>",
"      Condition (worn and faded garments may have reduced ratings)",
"     </li>",
"     <li>",
"      Finishing (some fabrics are treated with UV absorbing chemicals)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <a class=\"external\" href=\"file://www.skincancer.org/prevention/seal-of-recommendation\">",
"     Skin Cancer Foundation",
"    </a>",
"    in the United States has developed a list of products, including cosmetics, clothes, and laundry additives, that can provide sun protection.",
"   </p>",
"   <p>",
"    The UPF classification is certified by national and international organizations (eg, American Sun Protection Association, Skin Cancer Foundation). The categories are UPF 15 to 24 for good protection, 25 to 39 for very good protection, and 40 to 50 for excellent protection. The tightness of the weave probably contributes more than other factors to the UPF of a garment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33447/abstract/41\">",
"     41",
"    </a>",
"    ]. A garment&rsquo;s photoprotective capacity may also be enhanced by washing with detergents containing optical whitening agents. Shrinkage from repeated washing and drying may actually improve the UPF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11208773\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sunscreens are topical preparations containing inorganic (mineral) or organic substances that reflect and scatter or absorb UV radiation in the UVB and UVA wavelength range (",
"      <a class=\"graphic graphic_table graphicRef73127 \" href=\"mobipreview.htm?6/27/6589\">",
"       table 1",
"      </a>",
"      ). Broad-spectrum sunscreens are generally combinations of sunscreen products that absorb both UVB and UVA radiations. (See",
"      <a class=\"local\" href=\"#H25103687\">",
"       'Inorganic filters'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H66298617\">",
"       'Organic filters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Everyone, regardless of skin phototype (",
"      <a class=\"graphic graphic_table graphicRef60541 \" href=\"mobipreview.htm?15/37/15963\">",
"       table 2",
"      </a>",
"      ), is subject to the potential adverse effects of UV radiation and may benefit from sunscreen. However, sunscreens are especially useful for individuals with light skin (phototypes I, II, and III) (",
"      <a class=\"graphic graphic_table graphicRef60541 \" href=\"mobipreview.htm?15/37/15963\">",
"       table 2",
"      </a>",
"      ) who are more susceptible to sunburn, photoaging, and skin cancer. (See",
"      <a class=\"local\" href=\"#H11208302\">",
"       'Who should use sunscreen?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Broad spectrum products with SPF30 or higher are recommended for individuals performing outdoor work, sports, or recreational activities. (See",
"      <a class=\"local\" href=\"#H9546106\">",
"       'Selection of sunscreen products'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sunscreens must be applied liberally, repeatedly, and to all sun-exposed parts of the skin to provide effective protection. Sunscreen should be applied 15 to 30 minutes before sun exposure to allow the formation of a protective film on the skin, and reapplied every two hours. (See",
"      <a class=\"local\" href=\"#H9546113\">",
"       'Proper use of sunscreens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sunscreens generally have an excellent safety profile and there is no evidence of systemic adverse effects related to percutaneous absorption. However, sunscreens may rarely induce allergic and irritant contact dermatitis, phototoxic and photoallergic reactions, or contact urticaria. (See",
"      <a class=\"local\" href=\"#H9546127\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wearing clothes is important for sun protection. The degree of photoprotection provided by clothes is defined by the ultraviolet protection factor (UPF), which indicates how effective a fabric is at blocking out solar ultraviolet radiation. Yarn composition, tightness of the weave, and dark colors increase a garment&rsquo;s UPF. (See",
"      <a class=\"local\" href=\"#H9546141\">",
"       'Photoprotective clothing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/1\">",
"      de Gruijl FR, Rebel H. Early events in UV carcinogenesis--DNA damage, target cells and mutant p53 foci. Photochem Photobiol 2008; 84:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/2\">",
"      Yaar M, Gilchrest BA. Photoageing: mechanism, prevention and therapy. Br J Dermatol 2007; 157:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/3\">",
"      Tewari A, Sarkany RP, Young AR. UVA1 induces cyclobutane pyrimidine dimers but not 6-4 photoproducts in human skin in vivo. J Invest Dermatol 2012; 132:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/4\">",
"      Hexsel CL, Bangert SD, Hebert AA, Lim HW. Current sunscreen issues: 2007 Food and Drug Administration sunscreen labelling recommendations and combination sunscreen/insect repellent products. J Am Acad Dermatol 2008; 59:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/5\">",
"      Fourtanier A, Moyal D, Seite S. UVA filters in sun-protection products: regulatory and biological aspects. Photochem Photobiol Sci 2012; 11:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/6\">",
"      Ou-Yang H, Stanfield JW, Cole C, Appa Y. An evaluation of ultraviolet A protection and photo-stability of sunscreens marketed in Australia and New Zealand. Photodermatol Photoimmunol Photomed 2010; 26:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/7\">",
"      Sambandan DR, Ratner D. Sunscreens: an overview and update. J Am Acad Dermatol 2011; 64:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/8\">",
"      Lautenschlager S, Wulf HC, Pittelkow MR. Photoprotection. Lancet 2007; 370:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/9\">",
"      Wang SQ, Tooley IR. Photoprotection in the era of nanotechnology. Semin Cutan Med Surg 2011; 30:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/10\">",
"      Shukla RK, Kumar A, Pandey AK, et al. Titanium dioxide nanoparticles induce oxidative stress-mediated apoptosis in human keratinocyte cells. J Biomed Nanotechnol 2011; 7:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/11\">",
"      Gamer AO, Leibold E, van Ravenzwaay B. The in vitro absorption of microfine zinc oxide and titanium dioxide through porcine skin. Toxicol In Vitro 2006; 20:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/12\">",
"      Zvyagin AV, Zhao X, Gierden A, et al. Imaging of zinc oxide nanoparticle penetration in human skin in vitro and in vivo. J Biomed Opt 2008; 13:064031.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/forconsumers/consumerupdates/ucm258416.htm (Accessed on August 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/14\">",
"      Wang SQ, Lim HW. Current status of the sunscreen regulation in the United States: 2011 Food and Drug Administration's final rule on labeling and effectiveness testing. J Am Acad Dermatol 2011; 65:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/15\">",
"      Draelos ZD. The multifunctional value of sunscreen-containing cosmetics. Skin Therapy Lett 2011; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/16\">",
"      Draelos ZD. Compliance and sunscreens. Dermatol Clin 2006; 24:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/17\">",
"      Tanner PR. Sunscreen product formulation. Dermatol Clin 2006; 24:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/18\">",
"      Avenel-Audran M, Dutartre H, Goossens A, et al. Octocrylene, an emerging photoallergen. Arch Dermatol 2010; 146:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/19\">",
"      Darlington S, Williams G, Neale R, et al. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol 2003; 139:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/20\">",
"      Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/21\">",
"      van der Pols JC, Williams GM, Pandeya N, et al. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 2006; 15:2546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/22\">",
"      Hackenberg S, Kleinsasser N. Dermal toxicity of ZnO nanoparticles: a worrying feature of sunscreen? Nanomedicine (Lond) 2012; 7:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/23\">",
"      Seit&eacute; S, Colige A, Piquemal-Vivenot P, et al. A full-UV spectrum absorbing daily use cream protects human skin against biological changes occurring in photoaging. Photodermatol Photoimmunol Photomed 2000; 16:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/24\">",
"      Schleyer V, Weber O, Yazdi A, et al. Prevention of polymorphic light eruption with a sunscreen of very high protection level against UVB and UVA radiation under standardized photodiagnostic conditions. Acta Derm Venereol 2008; 88:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/25\">",
"      Lod&eacute;n M, Beitner H, Gonzalez H, et al. Sunscreen use: controversies, challenges and regulatory aspects. Br J Dermatol 2011; 165:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/26\">",
"      Skocaj M, Filipic M, Petkovic J, Novak S. Titanium dioxide in our everyday life; is it safe? Radiol Oncol 2011; 45:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/27\">",
"      Janjua NR, Mogensen B, Andersson AM, et al. Systemic absorption of the sunscreens benzophenone-3, octyl-methoxycinnamate, and 3-(4-methyl-benzylidene) camphor after whole-body topical application and reproductive hormone levels in humans. J Invest Dermatol 2004; 123:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/28\">",
"      Sharma V, Shukla RK, Saxena N, et al. DNA damaging potential of zinc oxide nanoparticles in human epidermal cells. Toxicol Lett 2009; 185:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/29\">",
"      Pfl&uuml;cker F, Wendel V, Hohenberg H, et al. The human stratum corneum layer: an effective barrier against dermal uptake of different forms of topically applied micronised titanium dioxide. Skin Pharmacol Appl Skin Physiol 2001; 14 Suppl 1:92.",
"     </a>",
"    </li>",
"    <li>",
"     Australian Government, Department of Health and ageing, Therapeutic Goods Administartion. A review of the scientific literature on the safety of nanoparticulate titanium dioxide or zinc oxide in sunscreens file://www.tga.gov.au/pdf/review-sunscreens-060220.pdf (Accessed on August 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/31\">",
"      Schauder S, Ippen H. Contact and photocontact sensitivity to sunscreens. Review of a 15-year experience and of the literature. Contact Dermatitis 1997; 37:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/32\">",
"      Agin PP, Ruble K, Hermansky SJ, McCarthy TJ. Rates of allergic sensitization and irritation to oxybenzone-containing sunscreen products: a quantitative meta-analysis of 64 exaggerated use studies. Photodermatol Photoimmunol Photomed 2008; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/33\">",
"      Schlumpf M, Cotton B, Conscience M, et al. In vitro and in vivo estrogenicity of UV screens. Environ Health Perspect 2001; 109:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/34\">",
"      Diehl JW, Chiu MW. Effects of ambient sunlight and photoprotection on vitamin D status. Dermatol Ther 2010; 23:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/35\">",
"      Faurschou A, Beyer DM, Schmedes A, et al. The relation between sunscreen layer thickness and vitamin D production after ultraviolet B exposure: a randomized clinical trial. Br J Dermatol 2012; 167:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/36\">",
"      Linos E, Keiser E, Kanzler M, et al. Sun protective behaviors and vitamin D levels in the US population: NHANES 2003-2006. Cancer Causes Control 2012; 23:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/37\">",
"      Norval M, Wulf HC. Does chronic sunscreen use reduce vitamin D production to insufficient levels? Br J Dermatol 2009; 161:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/38\">",
"      Lim HW, Gilchrest BA, Cooper KD, et al. Sunlight, tanning booths, and vitamin D. J Am Acad Dermatol 2005; 52:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/39\">",
"      Richardson SD. Environmental mass spectrometry: emerging contaminants and current issues. Anal Chem 2012; 84:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/40\">",
"      Danovaro R, Bongiorni L, Corinaldesi C, et al. Sunscreens cause coral bleaching by promoting viral infections. Environ Health Perspect 2008; 116:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33447/abstract/41\">",
"      Gies P. Photoprotection by clothing. Photodermatol Photoimmunol Photomed 2007; 23:264.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13751 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33447=[""].join("\n");
var outline_f32_42_33447=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11208773\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9546092\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9546099\">",
"      TYPES OF SUNSCREENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66298617\">",
"      Organic filters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25103687\">",
"      Inorganic filters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9424584\">",
"      Labeling and regulations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11208302\">",
"      WHO SHOULD USE SUNSCREEN?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9546106\">",
"      SELECTION OF SUNSCREEN PRODUCTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9424613\">",
"      SPF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9424629\">",
"      Spectrum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9424637\">",
"      Formulations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9546113\">",
"      PROPER USE OF SUNSCREENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9546120\">",
"      BENEFITS OF SUNSCREENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9424682\">",
"      Skin cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9424696\">",
"      Photoaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9424717\">",
"      Photodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9546127\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11208628\">",
"      Systemic absorption and toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11208635\">",
"      Irritant and allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11208664\">",
"      Hormonal effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4593870\">",
"      SUNSCREENS AND VITAMIN D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9546134\">",
"      ENVIRONMENTAL EFFECTS OF SUNSCREENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9546141\">",
"      PHOTOPROTECTIVE CLOTHING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11208773\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13751\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13751|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/8/15502\" title=\"figure 1\">",
"      Electromagnetic spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13751|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/27/6589\" title=\"table 1\">",
"      Sunscreens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/37/15963\" title=\"table 2\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23400?source=related_link\">",
"      Photoaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18426?source=related_link\">",
"      Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18073?source=related_link\">",
"      Primary prevention of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30136?source=related_link\">",
"      Sunburn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30968?source=related_link\">",
"      Treatment of actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_42_33448="Management of patent ductus arteriosus";
var content_f32_42_33448=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of patent ductus arteriosus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33448/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33448/contributors\">",
"     Thomas Doyle, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33448/contributors\">",
"     Ann Kavanaugh-McHugh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33448/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33448/contributors\">",
"     Jonathan Soslow, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33448/contributors\">",
"     Kevin Hill, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33448/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33448/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33448/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33448/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33448/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/42/33448/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ductus arteriosus (DA) is a fetal vascular connection between the main pulmonary artery and the aorta (",
"    <a class=\"graphic graphic_figure graphicRef65828 \" href=\"mobipreview.htm?10/31/10739\">",
"     figure 1",
"    </a>",
"    ) that diverts blood away from the pulmonary bed. After delivery, the DA undergoes active constriction and eventual obliteration. A patent ductus arteriosus (PDA) occurs when the DA fails to close postnatally. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8502?source=see_link\">",
"     \"Physiologic transition from intrauterine to extrauterine life\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of PDA in full-term infants, older children, and adults will be reviewed here. PDA in the premature infant, and the pathogenesis, clinical manifestations, and diagnosis of PDA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35656?source=see_link\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1002?source=see_link\">",
"     \"Management of patent ductus arteriosus in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR CLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a PDA, the primary management decision is whether to actively close the PDA, or to conservatively observe and monitor the patient's cardiac status on a regular basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Management approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    PDA closure is recommended for patients with a significant left-to-right shunt who are symptomatic, have evidence of left-sided volume overload (ie, left atrial or ventricular enlargement), or have reversible pulmonary arterial hypertension (PAH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/1\">",
"     1",
"    </a>",
"    ]. Closure results in resolution of symptoms and a decrease in the likelihood or severity of PAH, and the development of irreversible pulmonary vascular disease (Eisenmenger syndrome). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35656?source=see_link\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PDA closure is not recommended in patients with severe and irreversible PAH because of the procedural risk, the fact that closure does not improve survival, and right to left ductal shunting may be necessary to maintain cardiac output during episodes of increasing pulmonary vascular resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=see_link\">",
"     \"Medical management of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with either a small or silent PDA without a significant left-to-right shunt, the decision for PDA closure is less clear, and is discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Small PDA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric cardiologists generally recommend closure of a small audible PDA even in the absence of a significant left-to-right shunt based upon the belief that the long-term benefit of closure outweighs the risk of intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Closure eliminates the potential complications of PDA, particularly bacterial endocarditis, a recognized but uncommon complication of a small PDA. It is currently accomplished with minimal risks in children due to technologic advancements, such as percutaneous occlusion and video-assisted thoracoscopic (VAT) surgical ligation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Therapeutic interventions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In adults with a small PDA, the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    Task Force on Practice Guidelines suggests that consideration of percutaneous occlusion is reasonable even in the absence of left heart volume overload. If the PDA is left untreated, then routine follow-up every three to five years is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Silent PDA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of the \"silent ductus\", which has no audible murmur, is controversial. The silent PDA is detected incidentally by imaging studies (usually echocardiography, magnetic resonance imaging [MRI], or computed tomography [CT]) performed for other indications. As the sensitivity of two-dimensional and Doppler echocardiography has improved, this finding is encountered more frequently. Several studies have suggested that 0.5 to 1 percent of the population has a silent PDA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], though these studies may underestimate the true incidence.",
"   </p>",
"   <p>",
"    A silent PDA will never have hemodynamic consequences, and thus, the only impetus for closure is a theoretical increased risk of bacterial endocarditis. While there are case reports of bacterial endocarditis associated with a silent PDA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/8-11\">",
"     8-11",
"    </a>",
"    ], it is nearly impossible to estimate the risk of endocarditis without first knowing the true incidence of silent PDA. Some experts in the field believe all silent PDAs should be closed to prevent endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast, others believe that there is no increased risk of endocarditis in patients with a silent PDA compared to the general population, and, as a result, they believe routine closure is not warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/6,12,13\">",
"     6,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until more data are available, we recommend that the decision to close a silent PDA be individualized and based upon the physician and the",
"    <span class=\"nowrap\">",
"     patient/family's",
"    </span>",
"    preference after a discussion reviewing the risks and theoretical benefits of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     THERAPEUTIC INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions for PDA closure include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pharmacologic therapy, which is used exclusively in premature infants",
"     </li>",
"     <li>",
"      Surgical ligation",
"     </li>",
"     <li>",
"      Percutaneous catheter occlusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These interventions are described in the following sections. Management decisions regarding whether to close the PDA and, if so, which intervention to choose are discussed below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Management approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of prostaglandin synthesis, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , are used as the initial interventions for",
"   </p>",
"   <p>",
"    PDA closure in preterm infants. This intervention is based upon the observation that circulating prostaglandin E2 plays a key role in maintaining DA patency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35656?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\", section on 'Patency of the ductus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"     Indomethacin",
"    </a>",
"    has proven to be ineffective in term infants and older patients with a PDA. This is probably due to histologic differences between the ductus of a premature and a term infant. As a result, pharmacologic therapy is only used routinely in preterm infants. The pharmacologic therapy (ie, indomethacin and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) for PDA closure in the premature infant is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first successful case of surgical PDA ligation was performed in 1939 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/14\">",
"     14",
"    </a>",
"    ], and technical expertise gained over the last 70 years now allows this procedure to be performed safely even in extremely low birth weight infants (birth weight &lt;1000 g).",
"   </p>",
"   <p>",
"    The surgical approach and technique are dependent upon the size and age of the patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the premature infant, the procedure can be performed in the operating room, or at the bedside in the neonatal intensive care unit. It usually involves a posterolateral thoracotomy with anterior retraction of the lung. Closure is generally accomplished by a simple ligature. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1002?source=see_link&amp;anchor=H1214649#H1214649\">",
"       \"Management of patent ductus arteriosus in premature infants\", section on 'Surgical ligation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In term infants and older children, the surgical approach is similar with a posterolateral thoracotomy. The incision is generally through the third left intercostal space in infants, and the fourth left intercostal space in older patients. Many surgeons prefer multiple ligations or division to minimize the risk of recurrent shunt [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Percutaneous occlusion is the treatment of choice in the majority of adult patients. However, surgical closure may be needed when the ductal anatomy precludes device or coil closure (ie, large ductus, aneurysms, or infection) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/1,16\">",
"       1,16",
"      </a>",
"      ]. In these cases, surgical closure by thoracotomy or sternotomy, with or without cardiopulmonary bypass, is performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following complications are associated with surgical closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent laryngeal nerve paralysis",
"     </li>",
"     <li>",
"      Respiratory compromise",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Chylothorax",
"     </li>",
"     <li>",
"      Intracranial hemorrhage in preterm infants",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     VAT surgical ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video-assisted thoracoscopic (VAT) surgical ligation is a safe and effective procedure for PDA closure, and is less invasive than standard thoracotomy surgical closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/18\">",
"     18",
"    </a>",
"    ]. It involves isolation of the PDA using thoracoscopic techniques, and interruption of the PDA by placement of a surgical clip.",
"   </p>",
"   <p>",
"    In a large case series of 332 patients who underwent VAT surgical ductal ligation, only six patients had a residual shunt after the initial ductus interruption; five of these shunts closed after immediate clip repositioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/19\">",
"     19",
"    </a>",
"    ]. The main complication was recurrent laryngeal nerve dysfunction that was transient in five patients and persistent in only one patient. In this report, the mean operating time for this procedure was 20 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Percutaneous closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous PDA occlusion was first introduced in 1967 and provides an alternative to surgical ligation in patients beyond infancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Access is generally achieved through the femoral artery or vein. Patients usually are fully recovered after the procedure and can be discharged the same day or after an overnight observation.",
"   </p>",
"   <p>",
"    Although a variety of techniques have been developed, the two most commonly utilized techniques use coils (",
"    <a class=\"graphic graphic_picture graphicRef69599 \" href=\"mobipreview.htm?5/20/5447\">",
"     picture 1",
"    </a>",
"    ) or occlusion devices (",
"    <a class=\"graphic graphic_picture graphicRef73178 \" href=\"mobipreview.htm?40/41/41631\">",
"     picture 2",
"    </a>",
"    ), both of which result in successful PDA occlusion with normalization of left ventricular hemodynamics. In one case series of 37 children who underwent PDA closure either with coil occlusion or Amplatzer device, preprocedural elevations of left ventricular systolic and diastolic volumes, and serum N-terminal pro-brain natriuretic peptide returned to normal after PDA occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Coil occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the first use of coils to occlude the PDA in 1992 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/23\">",
"     23",
"    </a>",
"    ], a variety of deployment methods have been used to achieve complete and permanent occlusion by optimal coil positioning across the PDA (",
"    <a class=\"graphic graphic_picture graphicRef69599 \" href=\"mobipreview.htm?5/20/5447\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/24\">",
"     24",
"    </a>",
"    ]. Although, coils are highly efficacious and cost effective for occluding small PDAs, the rate of suboptimal outcomes (eg, coil embolization and residual shunt) rises with increasing ductal size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated from a large case series from the European Paediatric Cardiology Registry of 1291 attempted PDA coil occlusions in 1258 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/26\">",
"     26",
"    </a>",
"    ]. The median age of the patients was four years (range 0.1 to 52 years), and the median weight was 29 kg (range 1.8 to 100 kg). The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occlusion was achieved immediately in 59 percent of patients, which rose to 95 percent one year after the procedure.",
"     </li>",
"     <li>",
"      A suboptimal outcome occurred in 129 procedures (10 percent), including the failure to implant (53 patients, 4.2 percent), coil embolization (48 patients, 3.8 percent), residual leak requiring further intervention (16 patients, 1.3 percent), persistent hemolysis (11 patients, 0.9 percent), duct recanalization (3 patients), and flow impairment to adjacent structures (2 patients).",
"     </li>",
"     <li>",
"      Increasing PDA size was associated with increasing risk of an unfavorable outcome. Patients with a minimum PDA diameter greater than 2 mm had a 2.6 fold increase in a suboptimal outcome than the overall group (OR 2.6, 95% 2 to 3.2), and those with a PDA diameter greater than 4 mm had a 24-fold increased risk of an unfavorable outcome (OR 24, 95% CI 12 to 48).",
"     </li>",
"     <li>",
"      PDAs that were tubular in shape were also more likely to be associated with an unfavorable outcome (OR 2.4, OR 1.4 to 4). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35656?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and diagnosis of patent ductus arteriosus\", section on 'Ductal embryology and anatomy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although stainless steel coils were initially used, magnetic resonance imaging (MRI) compatible coils are the coil of choice for PDA occlusion. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'MRI compatibility'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Device occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;To circumvent the complications associated with larger PDAs, other devices have been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. However, many have a higher than acceptable rate of residual shunt or are cumbersome to use when applying to a moderate or large PDA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/30\">",
"     30",
"    </a>",
"    ]. The Amplatzer ductal occluder (ADO) has emerged as the most successful of the newly developed devices. Since its approval by the Food and Drug Administration in 2003, ADO is the device used most frequently in patients beyond the neonatal period for routine occlusion of moderate and large PDAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ADO device is a top-hat shaped, repositionable plug occluder made of nitinol wire mesh, which is delivered through a 5F to 7F long sheath (",
"    <a class=\"graphic graphic_picture graphicRef73178 \" href=\"mobipreview.htm?40/41/41631\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/34\">",
"     34",
"    </a>",
"    ]. A retention skirt extends radially around the distal part of the device and is positioned in the aortic ampulla, assuring secure fixation in the mouth of the PDA. Polyester fabric, which is sewn into the occluder, induces thrombosis that closes the communication.",
"   </p>",
"   <p>",
"    A case series reported the successful implantation of the ADO device in 435 of 484 patients (90 percent), age range 0.2 to 70.7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/30\">",
"     30",
"    </a>",
"    ]. Complete closure of the defect without residual shunt at the end of the procedure was noted in 76 percent of successful implants by angiography, with an increase in closure rate at 24 hours after the procedure to 88 percent demonstrated by echocardiography. Complications included one death, two cases of device embolization, and two cases of partial left pulmonary artery obstruction.",
"   </p>",
"   <p>",
"    In another case series of 205 patients who underwent implantation of a ADO device, immediate closure was noted in 44 percent, and subsequent closure rates increased to 66 and 97 percent based upon color Doppler echocardiography performed at 24 hours and one month after the procedure, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/32\">",
"     32",
"    </a>",
"    ]. All but one patient maintained complete occlusion at one year post-procedure. Device embolization occurred in 1.5 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Choice of occluders",
"    </span>",
"    &nbsp;&mdash;&nbsp;If percutaneous PDA occlusion is being considered, the choice of occluders (ie, coil versus device) is dependent upon the ductal size and morphology, and the size of the patient. While the ADO device is best suited for the conical ductus with the narrowest segment located at the PA end, it is relatively malleable and can adapt to a variety of ductal sizes and shapes. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Management approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two approaches for managing patients with PDA are observation and elective ductal closure. Management decisions are dependent upon the size of the left-to-right shunt, the age and size of the patient, and the family's choice regarding the benefits (ie, prevention of long-term complications associated with PDA) versus the risks of intervention. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications for closure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observation &mdash; If elective closure is deferred, antibiotic prophylaxis is not necessary for any medical or dental procedures in patients with either a silent or small PDA. Patients need to be evaluated on a regular basis to monitor for signs of increased cardiac workload",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary vascular changes. If these occur, PDA closure is recommended. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link&amp;anchor=H8#H8\">",
"       \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'AHA guideline'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H3\">",
"       'Small PDA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Silent PDA'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      PDA closure &mdash; Once the decision is made to proceed with PDA closure, the choice of therapeutic interventions is dependent upon the size and age of the patient, the size and morphology of the PDA, and the degree of shunting and symptomatology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the number of factors affecting the therapeutic choice for PDA closure, it is difficult to provide a simplified algorithm for management. Nonetheless, generalizations can be made to help simplify treatment decisions. In the following sections, the choice of treatment is based upon the age and size of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Premature infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;PDA frequently occurs in premature infants, especially extremely low birth weight infants (birth weight less than 1000 g). A significant left-to-right shunt may cause pulmonary edema and heart failure. In preterm infants, inhibitors of prostaglandin synthesis, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , are used as the initial interventions for PDA closure. The management of PDA in premature infants is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1002?source=see_link&amp;anchor=H17050117#H17050117\">",
"     \"Management of patent ductus arteriosus in premature infants\", section on 'Cyclooxygenase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Term and older infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Term and older infants (weight less than 6 kg) with significant left-to-right shunting generally present with cardiac and respiratory symptoms. Clinical manifestations of infants with large PDAs and heart failure include poor feeding, failure to thrive, respiratory distress, and sweating. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35656?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In infants with heart failure, medical management with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    can be instituted until the child is large enough (&ge;6 kg) to undergo percutaneous closure. If medical management fails or the PDA is of a size not felt to be suitable for device closure, surgical ligation is the treatment of choice. Inhibitors of prostaglandin synthesis (ie,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) are not effective in PDA closure in these patients, and thus are not recommended.",
"   </p>",
"   <p>",
"    In our institutions, infants without heart failure are observed with frequent monitoring of their cardiorespiratory status and growth until they are old enough to undergo percutaneous closure. If significant cardiorespiratory symptoms or growth impairment develop, medical management is initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although surgical ligation is a safe and effective procedure in children who weigh more than 6 kg, percutaneous occlusion is preferred because it is less invasive, does not result in a surgical scar, and is at least as cost effective, if not less expensive than surgical closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/12,35,36\">",
"     12,35,36",
"    </a>",
"    ]. Inhibitors of prostaglandin synthesis (ie,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) are ineffective in children and should not be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Occluder choice",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the child, the choice of occluders (coil versus device) is dependent upon ductal morphology and size, and the size of the patient.",
"   </p>",
"   <p>",
"    Numerous studies have documented the safety and efficacy of coil occlusion for a small PDA (&lt;3 mm in diameter) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/26\">",
"     26",
"    </a>",
"    ]. Although residual shunts are sometimes present immediately following coil occlusion, these shunts typically resolve after a few months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/26,37\">",
"     26,37",
"    </a>",
"    ]. As discussed above, outcomes using coils for occlusion may be suboptimal in cases with a window-like or tubular ductal morphology, or moderate to large PDA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/26\">",
"     26",
"    </a>",
"    ]. Although several techniques have been developed, including the use of large diameter (0.052 inch) coils and multiple coils delivered simultaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], coil occlusion of the moderate to large PDA is more complicated, requires longer fluoroscopy time, and has higher rates of embolization and residual shunts compared to device occluders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/26,40\">",
"     26,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of the limitations of coil occlusion of larger PDAs, device occlusion is increasingly being utilized. The Amplatzer ductal occluder (ADO) is the most commonly used device. However, it is not recommended for use in infants who weigh less than 6 kg, or who are less than six months of age, as the rate of major adverse events and failure of the device is high in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, the ductal ampulla must be able to accommodate the aortic retention disk (",
"    <a class=\"graphic graphic_picture graphicRef73178 \" href=\"mobipreview.htm?40/41/41631\">",
"     picture 2",
"    </a>",
"    ), which can cause coarctation of the aorta if it is too large for the child's vasculature or is improperly situated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Surgical ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the limitations of percutaneous closure in the small child, percutaneous closure may not be feasible or offered. Many institutions opt for surgical ligation as a safer alternative. Video assisted thorascopic (VAT) ligation is minimally invasive and can be safely performed in children of this size and age range. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Surgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Adolescents and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the older patient, percutaneous occlusion is the preferred intervention for PDA closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with a small PDA, coil occlusion can be used for PDA closure. For the moderate to large PDA, either coil or device occlusion can be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/1\">",
"     1",
"    </a>",
"    ]. Given the complexities and associated risk of complication with percutaneous occlusion of very large PDAs (&gt;14 mm), some centers opt for surgical ligation in this setting. In addition, surgical ligation is indicated in patients with distorted ductal morphology due to aneurysm or endarteritis that precludes device closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the older patient, an additional consideration is the potential for significant pulmonary vascular disease and pulmonary arterial hypertension (PAH). The American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association states that PDA closure may be considered in patients with PAH and left-to-right shunt. However, it is not always clear which patients with significant PAH will benefit from PDA occlusion. Patients with severe PAH (defined as a pulmonary vascular resistance &gt;6 Wood units x m&sup2; when breathing 100 percent oxygen) usually are not considered suitable candidates for correction of their shunt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/2\">",
"     2",
"    </a>",
"    ]. These patients generally have a higher",
"    <span class=\"nowrap\">",
"     operative/procedural",
"    </span>",
"    risk of complication or mortality, and often have progressive pulmonary vascular disease despite shunt repair.",
"   </p>",
"   <p>",
"    To help determine whether PDA closure should be performed in patients with PAH, assessment of the hemodynamic effects of temporary PDA occlusion as a measure of potentially reversible PAH has been advocated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/42\">",
"     42",
"    </a>",
"    ]. In one report of 29 adults (mean age 31.1, range 18 to 58 years) with PDAs and PAH, 20 patients underwent successful PDA occlusion after fulfilling the study's defined criteria for PAH reversibility during temporary PDA occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/42\">",
"     42",
"    </a>",
"    ]. These criteria included a fall or no change in pulmonary arterial pressure, no decrease in aortic pressure, and no worsening of symptoms. Short-term follow-up (three to six months after PDA occlusion) demonstrated improvement in symptomatology, and decreases in the sizes of the left atrium, left ventricular diastolic dimension, and pulmonary artery. However, an editorial accompanying this report raised concerns about such a strategy because of the potential of long-term morbidity and mortality associated with the removal of a potential right-to-left shunt, which may be needed to maintain cardiac output during episodes of increasing pulmonary vascular resistance due to progressive pulmonary vascular changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/2\">",
"     2",
"    </a>",
"    ]. Until data are available regarding the long-term outcome of this strategy, we continue to use the generally accepted guidelines of deferring PDA closure in adult patients with severe PAH.",
"   </p>",
"   <p>",
"    As discussed previously, in patients with severe PAH that has resulted in a right-to-left shunt (ie, Eisenmenger syndrome), PDA closure is not indicated because of the need to maintain the shunt to avoid heart failure and maintain cardiac output. Medical management of patients with Eisenmenger syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=see_link\">",
"     \"Medical management of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     POSTOCCLUSION MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults undergoing percutaneous device occlusion, once full closure is documented by echocardiography, follow-up is recommended at least every five years, as there are limited data on the long-term outcomes of percutaneous occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33448/abstract/1\">",
"     1",
"    </a>",
"    ]. In children, there are no written recommendations for long-term follow-up. Many pediatric cardiologists are comfortable discharging children from follow-up after six months to a year if there is no residual shunt, no pulmonary artery distortion or stenosis, and no aortic obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473485410\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following percutaneous closure, antibiotic prophylaxis is given for six months, at which point the medical hardware is considered to be fully endothelialized, and there is no longer an increased risk of endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     MRI compatibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stainless steel coils are ferrous and can be affected by the magnetic resonance imaging (MRI) field. This should be taken into account when considering performing MRI on a patient with a PDA coil. The Amplatzer ductal occluder (ADO) is considered to be MRI compatible and safe, provided the following MRI limits are used.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Static magnetic field of 3T or less",
"     </li>",
"     <li>",
"      Spatial gradient magnetic field of 720",
"      <span class=\"nowrap\">",
"       G/cm",
"      </span>",
"      or less",
"     </li>",
"     <li>",
"      Maximum MR system-reported, whole-body-averaged specific absorption rate (SAR) of",
"      <span class=\"nowrap\">",
"       3W/kg",
"      </span>",
"      for 15 minutes of scanning",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Image quality may be distorted in the area of the coils and devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy in women with congenital heart disease (unrepaired or repaired) poses potential risks to the mother and fetus. The general principles of this problem are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/7/29818?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unrepaired PDA is a cause of left-to-right shunt that may be encountered among expectant mothers, although operative or interventional catheter closure is routine and curative in childhood. Most commonly, an asymptomatic young woman with a restrictive (ie, small) PDA can anticipate an uncomplicated pregnancy. Less frequently, moderate or large unrepaired PDA with significant shunting and concomitant abnormalities of pulmonary vascular resistance complicates pregnancy.",
"   </p>",
"   <p>",
"    In the case of left-to-right ductal shunting, the gestational fall in systemic vascular resistance may serve to decrease ductal flow, but this benefit is unlikely to compensate for the hemodynamic burden of pregnancy. Patients with a nonrestrictive PDA, pulmonary vascular disease, and a reversed shunt (ie, Eisenmenger syndrome) are at high risk for significant morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical management of Eisenmenger syndrome\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Division of a restrictive or moderately restrictive PDA in childhood is considered curative. However, closure of a nonrestrictive ductus may be followed by an incomplete decline in pulmonary vascular resistance or by incomplete functional recovery of the volume-overloaded left ventricle or the pressure-overloaded right ventricle. Postoperative pulmonary vascular disease and depressed ventricular function are important residua that can increase gestational risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ductus arteriosus (DA) is a fetal vascular connection between the main pulmonary artery and the aorta that normally closes soon after birth (",
"    <a class=\"graphic graphic_figure graphicRef65828 \" href=\"mobipreview.htm?10/31/10739\">",
"     figure 1",
"    </a>",
"    ). A patent ductus arteriosus (PDA) occurs when the DA fails to close postnatally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Indications for PDA closure",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend PDA closure for patients with a significant left-to-right shunt who are symptomatic, have evidence of left cardiac overload (ie, left atrial or ventricular enlargement), or have mild to moderate pulmonary arterial hypertension (PAH) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend PDA closure for patients with a previous episode of endocarditis regardless of the size of PDA in the absence of severe PAH (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest closure of small but audible PDAs even in the absence of a significant left-to-right shunt, because we believe the long-term benefit of closure (eg, prevention of endocarditis) outweighs the risk of intervention, especially in infants and children (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An alternative approach is to defer PDA closure and routinely follow patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Small PDA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of silent PDAs (no audible murmur) is controversial. In our institution, the decision for PDA closure is made on an individual basis, primarily based upon physician and",
"      <span class=\"nowrap\">",
"       patient/family",
"      </span>",
"      preference. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Silent PDA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest observation rather than closure of PDAs in patients with severe PAH",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      right-to-left shunt (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These patients have or are likely to develop Eisenmenger syndrome (PAH, right-to-left shunting, and cyanosis) and may need the shunt to maintain cardiac output. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=see_link\">",
"       \"Medical management of Eisenmenger syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions for ductal closure include pharmacologic therapy, which is used exclusively in premature infants, percutaneous catheter occlusion, and surgical ligation. Once the decision is made for PDA closure, the age and size of the patient, and the availability of experienced clinicians to perform the procedure dictate the choice of intervention. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Therapeutic interventions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Management approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premature infants (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1002?source=see_link\">",
"       \"Management of patent ductus arteriosus in premature infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Term and older infants (below 6 kg in weight) who have symptomatic PDAs, are medically treated (ie, lasix",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      ) until they are large enough to safely undergo percutaneous PDA occlusion. If the patient fails medical therapy or the PDA is not suitable for device closure, surgical ligation is indicated. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Term and older infants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with indications for PDA closure, we suggest percutaneous PDA closure, which should be performed in centers with experienced pediatric interventional cardiologists (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Surgical ligation is a reasonable alternative option if these services are not available. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In adolescents and adults, we recommend percutaneous PDA closure performed by experienced pediatric interventional cardiologists (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients who undergo percutaneous PDA closure, the choice of occluders (coil versus device) is dependent upon the ductal morphology and size, and the size of the patient. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Percutaneous closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic antibiotics are only indicated for six months after percutaneous PDA closure. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Postocclusion management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"       \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/1\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/2\">",
"      Rigby ML. Closure of a large patent ductus arteriosus in adults: first do no harm. Heart 2007; 93:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/3\">",
"      Campbell M. Natural history of persistent ductus arteriosus. Br Heart J 1968; 30:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/4\">",
"      Huggon IC, Qureshi SA. Is the prevention of infective endarteritis a valid reason for closure of the patent arterial duct? Eur Heart J 1997; 18:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/5\">",
"      Giroud JM, Jacobs JP. Evolution of strategies for management of the patent arterial duct. Cardiol Young 2007; 17 Suppl 2:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/6\">",
"      Lloyd TR, Beekman RH 3rd. Clinically silent patent ductus arteriosus. Am Heart J 1994; 127:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/7\">",
"      Houston AB, Gnanapragasam JP, Lim MK, et al. Doppler ultrasound and the silent ductus arteriosus. Br Heart J 1991; 65:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/8\">",
"      Celebi A, Erdem A, Coku��ra�� H, Ahunbay G. Infective endarteritis in a 2-month-old infant associated with silent patent ductus arteriosus. Anadolu Kardiyol Derg 2007; 7:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/9\">",
"      Parthenakis FI, Kanakaraki MK, Vardas PE. Images in cardiology: silent patent ductus arteriosus endarteritis. Heart 2000; 84:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/10\">",
"      Onji K, Matsuura W. Pulmonary endarteritis and subsequent pulmonary embolism associated with clinically silent patent ductus arteriosus. Intern Med 2007; 46:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/11\">",
"      Ozkokeli M, Ates M, Uslu N, Akcar M. Pulmonary and aortic valve endocarditis in an adult patient with silent patent ductus arteriosus. Jpn Heart J 2004; 45:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/12\">",
"      Prieto LR, DeCamillo DM, Konrad DJ, et al. Comparison of cost and clinical outcome between transcatheter coil occlusion and surgical closure of isolated patent ductus arteriosus. Pediatrics 1998; 101:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/13\">",
"      Thil&eacute;n U, Astr&ouml;m-Olsson K. Does the risk of infective endarteritis justify routine patent ductus arteriosus closure? Eur Heart J 1997; 18:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/14\">",
"      Gross RE, Hubbard JP. Landmark article Feb 25, 1939: Surgical ligation of a patent ductus arteriosus. Report of first successful case. By Robert E. Gross and John P. Hubbard. JAMA 1984; 251:1201.",
"     </a>",
"    </li>",
"    <li>",
"     Mavroudis, C, and Backer CL. Pediatric Cardiac Surgery, 3rd ed, Mosby-Year Book Inc, Philadelphia, 2003. p. 875.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/16\">",
"      Omari BO, Shapiro S, Ginzton L, et al. Closure of short, wide patent ductus arteriosus with cardiopulmonary bypass and balloon occlusion. Ann Thorac Surg 1998; 66:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/17\">",
"      Clyman RI. Ibuprofen and patent ductus arteriosus. N Engl J Med 2000; 343:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/18\">",
"      Bensky AS, Raines KH, Hines MH. Late follow-up after thoracoscopic ductal ligation. Am J Cardiol 2000; 86:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/19\">",
"      Laborde F, Folliguet TA, Etienne PY, et al. Video-thoracoscopic surgical interruption of patent ductus arteriosus. Routine experience in 332 pediatric cases. Eur J Cardiothorac Surg 1997; 11:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/20\">",
"      Porstmann W, Wierny L, Warnke H. Closure of persistent ductus arteriosus without thoracotomy. Ger Med Mon 1967; 12:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/21\">",
"      Wierny L, Plass R, Porstmann W. Transluminal closure of patent ductus arteriosus: long-term results of 208 cases treated without thoracotomy. Cardiovasc Intervent Radiol 1986; 9:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/22\">",
"      Eerola A, Jokinen E, Boldt T, Pihkala J. The influence of percutaneous closure of patent ductus arteriosus on left ventricular size and function: a prospective study using two- and three-dimensional echocardiography and measurements of serum natriuretic peptides. J Am Coll Cardiol 2006; 47:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/23\">",
"      Cambier PA, Kirby WC, Wortham DC, Moore JW. Percutaneous closure of the small (less than 2.5 mm) patent ductus arteriosus using coil embolization. Am J Cardiol 1992; 69:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/24\">",
"      Ebeid MR, Gaymes CH, Smith JC, et al. Gianturco-Grifka vascular occlusion device for closure of patent ductus arteriosus. Am J Cardiol 2001; 87:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/25\">",
"      Benson L, McLaughlin PR, Webb GD. The European experience with coil occlusion of PDA: strength in numbers. Eur Heart J 2001; 22:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/26\">",
"      Magee AG, Huggon IC, Seed PT, et al. Transcatheter coil occlusion of the arterial duct; results of the European Registry. Eur Heart J 2001; 22:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/27\">",
"      Rashkind WJ, Mullins CE, Hellenbrand WE, Tait MA. Nonsurgical closure of patent ductus arteriosus: clinical application of the Rashkind PDA Occluder System. Circulation 1987; 75:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/28\">",
"      Grifka RG, Vincent JA, Nihill MR, et al. Transcatheter patent ductus arteriosus closure in an infant using the Gianturco-Grifka Vascular Occlusion Device. Am J Cardiol 1996; 78:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/29\">",
"      Bridges ND, Perry SB, Parness I, et al. Transcatheter closure of a large patent ductus arteriosus with the clamshell septal umbrella. J Am Coll Cardiol 1991; 18:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/30\">",
"      Pass RH, Hijazi Z, Hsu DT, et al. Multicenter USA Amplatzer patent ductus arteriosus occlusion device trial: initial and one-year results. J Am Coll Cardiol 2004; 44:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/31\">",
"      Thanopoulos BD, Hakim FA, Hiari A, et al. Further experience with transcatheter closure of the patent ductus arteriosus using the Amplatzer duct occluder. J Am Coll Cardiol 2000; 35:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/32\">",
"      Bilkis AA, Alwi M, Hasri S, et al. The Amplatzer duct occluder: experience in 209 patients. J Am Coll Cardiol 2001; 37:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/33\">",
"      Thanopoulos BV, Eleftherakis N, Tzannos K, et al. Further experience with catheter closure of patent ductus arteriosus using the new Amplatzer duct occluder in children. Am J Cardiol 2010; 105:1005.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.amplatzer.com/products/pda_devices/tabid/193/default.aspx.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/35\">",
"      Dutta S, Mihailovic A, Benson L, et al. Thoracoscopic ligation versus coil occlusion for patent ductus arteriosus: a matched cohort study of outcomes and cost. Surg Endosc 2008; 22:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/36\">",
"      Feltes TF, Bacha E, Beekman RH 3rd, et al. Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association. Circulation 2011; 123:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/37\">",
"      Celiker A, Aypar E, Karag&ouml;z T, et al. Transcatheter closure of patent ductus arteriosus with Nit-Occlud coils. Catheter Cardiovasc Interv 2005; 65:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/38\">",
"      Kumar RK, Krishnan MN, Venugopal K, et al. Bioptome-assisted simultaneous delivery of multiple coils for occlusion of the large patent ductus arteriosus. Catheter Cardiovasc Interv 2001; 54:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/39\">",
"      Hijazi ZM, Geggel RL. Transcatheter closure of large patent ductus arteriosus (&gt; or = 4 mm) with multiple Gianturco coils: immediate and mid-term results. Heart 1996; 76:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/40\">",
"      Galal MO. Advantages and disadvantages of coils for transcatheter closure of patent ductus arteriosus. J Interv Cardiol 2003; 16:157.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.amplatzer.com/portals/aga/uploaded_docs/AMPLATZER_Duct_Occluder_Instructions_For_Use_United_States_Only_04_28_08.pdf (accessed June 11, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33448/abstract/42\">",
"      Yan C, Zhao S, Jiang S, et al. Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart 2007; 93:514.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5771 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33448=[""].join("\n");
var outline_f32_42_33448=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR CLOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Small PDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Silent PDA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      THERAPEUTIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - VAT surgical ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Percutaneous closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Coil occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Device occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Choice of occluders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Premature infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Term and older infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Occluder choice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Surgical ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      POSTOCCLUSION MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473485410\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MRI compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Indications for PDA closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5771\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5771|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/31/10739\" title=\"figure 1\">",
"      Pathophysiology PDA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5771|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/20/5447\" title=\"picture 1\">",
"      PDA closure Glanturco coils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/41/41631\" title=\"picture 2\">",
"      Amplatzer ductal occluder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1002?source=related_link\">",
"      Management of patent ductus arteriosus in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=related_link\">",
"      Medical management of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8502?source=related_link\">",
"      Physiologic transition from intrauterine to extrauterine life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_42_33449="Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)";
var content_f32_42_33449=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33449/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33449/contributors\">",
"     Paul Saenger, MD, MACE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33449/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33449/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33449/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33449/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33449/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33449/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33449/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/42/33449/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Turner syndrome is an important cause of short stature in girls and primary amenorrhea in young women that is usually caused by loss of part or all of an X-chromosome. The clinical manifestations and diagnosis of Turner syndrome will be reviewed here. Treatment of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14329?source=see_link\">",
"     \"Management of Turner syndrome (gonadal dysgenesis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Turner syndrome, first described in 1938 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/1\">",
"     1",
"    </a>",
"    ], is the most common sex-chromosome abnormality that occurs in approximately",
"    <span class=\"nowrap\">",
"     1/2,500",
"    </span>",
"    live female births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/2\">",
"     2",
"    </a>",
"    ].The true prevalence of Turner syndrome is difficult to ascertain since those with mild phenotypic features may remain undiagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular studies have shown that the maternal X is retained in two-thirds of patients with Turner syndrome and the paternal X in the remaining one-third [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/4\">",
"     4",
"    </a>",
"    ]. More than one-half of all patients with Turner syndrome have a mosaic chromosomal complement (eg,",
"    <span class=\"nowrap\">",
"     45,X/46,XX)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Mosaicism with a normal cell line in the fetal membranes may be necessary for adequate placental function and fetal survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The identification of mosaicism depends directly upon the method of ascertainment. It varies from 34 percent with conventional cytogenetic techniques to 60 percent with fluorescence in situ hybridization techniques to 74 percent in a study in which reverse transcriptase polymerase-chain-reaction assays were used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with Turner syndrome lack only part of one sex chromosome, and the Turner syndrome phenotype can be seen with a variety of structural abnormalities, such as rings, isochromosomes, or terminal deletions. A rare but very informative class of Turner syndrome includes patients who have deletions of the Y chromosome that remove the testes-determining gene, SRY; these individuals develop as females. Based upon this finding and the fact that males require only one X-chromosome for normal development, Ferguson-Smith hypothesized that copies of Turner syndrome genes are also present on the Y-chromosome.",
"   </p>",
"   <p>",
"    Specific localization of Turner syndrome candidate genes proved elusive until one group successfully identified a pseudo-autosomal deletion encompassing a novel homeobox gene, SHOX (short stature homeobox-containing gene on the X-chromosome), which is associated with short stature in idiopathic short stature, Leri-Weill dyschondrosteosis, and Turner syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tips of the short arms of chromosomes X and Y are logical sites for Turner syndrome genes, as sex chromosomes undergo meiotic recombination within the pseudo-autosomal region and all genes in this region that have been examined escape X-inactivation. Characterization of XYp-females provides additional support for the hypothesis of a distinct Turner syndrome stature locus: most of these patients have unbalanced X,Y translocations and, in the most fully documented patients with this karyotype, two intact copies of the pseudo-autosomal region are present. It is not surprising that these patients attain normal stature, despite the presence of features consistent with Turner syndrome. As noted above, the Short Stature Homeobox-containing Gene (SHOX) was identified as the genetic cause of the short stature phenotype in patients with Turner Syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies that have examined the relationship between the chromosomal and karyotypic abnormalities and clinical findings in patients with Turner syndrome have been disappointing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/12\">",
"     12",
"    </a>",
"    ]. Short stature is the only clinical finding invariably associated with the 45,X karyotype; it also is the only phenotypic abnormality present in virtually 100 percent of patients. Karyotypic abnormalities may also correlate with the presence of hypothyroidism (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Autoimmune disorders'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Deletions of the long arm of the X chromosome have been reported in otherwise normal women (ie, normal stature) with secondary amenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with Turner syndrome are short and stocky and have a squarely shaped chest (",
"    <a class=\"graphic graphic_table graphicRef60006 \" href=\"mobipreview.htm?12/38/12910\">",
"     table 1",
"    </a>",
"    ). Neonates may have congenital lymphedema of the hands and feet and two or more of the following dysmorphic features: webbed neck, nail dysplasia, high palate, and short fourth metacarpal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/14\">",
"     14",
"    </a>",
"    ]. The height of patients with Turner syndrome should be plotted on growth curves specific for this disorder (",
"    <a class=\"graphic graphic_figure graphicRef75558 \" href=\"mobipreview.htm?33/21/34129\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hearing loss, hypothyroidism, and liver function abnormalities can occur as these women get older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Liver enzymes are elevated in approximately 35 to 45 percent of adult patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], and improve with postmenopausal hormone therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/19\">",
"     19",
"    </a>",
"    ]. Intelligence is usually within the normal range, but patients may have specific neurocognitive deficits, eg, problems with visuo-spatial organization. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Psychologic and educational issues'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other manifestations include autoimmune diseases (including chronic autoimmune thyroiditis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/21\">",
"     21",
"    </a>",
"    ], and specific morphologic defects of facial development and cardiovascular, urologic, and bone structure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/17,22,23\">",
"     17,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ovarian failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most affected women have no pubertal development and primary amenorrhea, some develop normally and then have secondary amenorrhea, while occasionally others have no morphologic defects and achieve normal stature.",
"   </p>",
"   <p>",
"    As an example, a retrospective study of 522 patients with Turner syndrome who were over the age of 12 years found that 84 (16 percent) had spontaneous menarche at an average age of 13.2 years; 30 of these women still had regular menses nine years after menarche, and three became pregnant without medical assistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a second retrospective study of 276 adults with cytogenetically proven Turner syndrome, five women had spontaneous puberty and spontaneous pregnancies, despite high-grade monosomy (45,X in &ge;90 percent of a 50-cell karyotype) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Manifestations in older patients include primary hypogonadism occurring either before or after puberty (gonadal dysgenesis). It is one of the most common causes of premature ovarian failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7817?source=see_link\">",
"     \"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ovaries in Turner syndrome characteristically consist of small amounts of connective tissue and no follicles or only a few atretic follicles (\"streak gonads\"). However, the degree of ovarian dysfunction and the extent of the defects are variable.",
"   </p>",
"   <p>",
"    Careful histologic studies of the ovaries of eight aborted 45,X fetuses many years ago are the basis of our understanding of the gonadal failure in Turner syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/26\">",
"     26",
"    </a>",
"    ]. These ovaries contained apparently normal numbers of primordial germ cells for up to at least six weeks of gestation, but at later gestational ages, the numbers of germ cells were decreased and connective tissue was increased, as compared with age-matched normal fetuses. These results indicate that the gonadal dysgenesis may be caused by accelerated apoptosis rather than abnormal germ cell formation.",
"   </p>",
"   <p>",
"    Another study evaluated 104 girls aged 0.2 to 17.4 years with complete or partial X-chromosome deletions using pelvic ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/27\">",
"     27",
"    </a>",
"    ]. Approximately one-third had visible, non-streak ovaries. The girls with visible ovaries had apparently normal ovarian growth and follicular development up to the time of puberty, and were more likely to have spontaneous breast development and uterine growth, indicating some ovarian function; many, but not all, of these girls had incomplete X-chromosome deletions. These findings are consistent with several case reports of adult women with both 45,X and partial X deletions who have conceived and borne children before developing secondary amenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the consequences of X-chromosome deletions are highly variable, ranging (at the extremes) from intrauterine death to normal health with normal menarche and normal reproductive function for a few years thereafter. The incidence of 45,X and",
"    <span class=\"nowrap\">",
"     45,X/46,XX",
"    </span>",
"    mosaic karyotypes in women with normal fertility is unknown.",
"   </p>",
"   <p>",
"    Only one X chromosome is active in somatic cells after the third week of gestation. As a result, a deletion of any part of one X-chromosome will affect fertility only if the normal copies of the missing gene or genes do one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Imprint somatic cells before three weeks of gestation",
"     </li>",
"     <li>",
"      Escape inactivation so that two copies are normally required",
"     </li>",
"     <li>",
"      Are critical for oocyte development (since oocytes have two active X-chromosomes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Short stature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short stature combined with a square appearance is the most common clinical feature of Turner syndrome. The adult height of untreated patients correlates significantly with mid-parental height (ie, the height corresponds to the average of the height percentiles of the mother and the father).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/54/12137?source=see_link\">",
"     Recombinant human growth hormone",
"    </a>",
"    therapy is recommended to maximize final height. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14329?source=see_link\">",
"     \"Management of Turner syndrome (gonadal dysgenesis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Renal anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal anomalies are common in patients with Turner syndrome. Approximately 30 to 50 percent have a renal malformation, most commonly horseshoe kidney, followed by abnormal vascular supply [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/3,30,31\">",
"     3,30,31",
"    </a>",
"    ]. Patients should undergo renal ultrasonography at the time of diagnosis and, if structural abnormalities are identified, they should be monitored yearly for urinary tract infection (",
"    <a class=\"graphic graphic_table graphicRef50455 graphicRef63261 graphicRef73981 \" href=\"mobipreview.htm?11/20/11598\">",
"     table 2A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Anomalies associated with obstruction of the ureteropelvic junction can produce clinically significant hydronephrosis or pyelonephritis. Idiopathic hypertension is common in Turner syndrome, even in the absence of recognizable renal or cardiac malformations. Blood pressure should therefore be monitored carefully, and hypertension treated vigorously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased risk of cardiovascular morbidity in women with Turner syndrome, presumably due to their risk of cardiovascular malformations, renal abnormalities, and hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/32\">",
"     32",
"    </a>",
"    ]. Abnormalities include coarctation, aortic valvular disease, aortic dissection, hypertension, and other cardiovascular anomalies. Mortality rates are also increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Coarctation/aortic valve disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of cardiovascular malformations in patients with Turner syndrome is variable across studies. Approximately 20 to 30 percent have aortic valve disease, while 3 to 10 percent have coarctation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. In one report of 179 patients, the prevalence of cardiovascular malformations was higher in those with 45,X compared with those with a mosaic chromosomal complement",
"    <span class=\"nowrap\">",
"     (45,X/46,XX)",
"    </span>",
"    (38 versus 11 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a second series of 253 individuals with Turner syndrome, aortic root dilation, coarctation, and neck webbing were all associated with the presence of bicuspid aortic valve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/35\">",
"     35",
"    </a>",
"    ]. The variability among these estimates could be due to differences in the age group examined, the degree of mosaicism in the population, or to technical difficulty in visualizing the valvular defect using echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even when initial magnetic resonance imaging does not show aortic root dilation or coarctation, subsequent imaging may show the development of these abnormalities during the next two to six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Aortic dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic dissection or rupture is an increasingly recognized cause of death in women with Turner syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In a study of 166 women with Turner syndrome and 26 healthy controls, one-third of the patients had aortic size index values (ascending aortic diameters normalized to body surface area) greater than the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile (2.0",
"    <span class=\"nowrap\">",
"     cm/m2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/38\">",
"     38",
"    </a>",
"    ]. After three years of follow-up, aortic dissections occurred in three patients (all three had an aortic size index &gt;2.5",
"    <span class=\"nowrap\">",
"     cm/m2),",
"    </span>",
"    for an annualized rate of 618",
"    <span class=\"nowrap\">",
"     cases/100,000",
"    </span>",
"    woman-years, approximately 100-fold higher than that seen in women of similar age without Turner syndrome. In a report of 20 women with Turner syndrome who had already experienced an aortic dissection, mean aortic size index was 2.7 &plusmn;0.6",
"    <span class=\"nowrap\">",
"     cm/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523815943\">",
"    <span class=\"h4\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of greater concern is a possible increase in mortality due to aortic dissection or rupture that has been reported in women with Turner syndrome achieving pregnancy through IVF with oocyte donation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/40\">",
"     40",
"    </a>",
"    ]. Therefore, before attempting to become pregnant, women with Turner syndrome should undergo a complete medical evaluation, with particular attention paid to cardiovascular and renal function, as recommended by the American Society of Reproductive Medicine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14329?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of Turner syndrome (gonadal dysgenesis)\", section on 'Fertility'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24807?source=see_link\">",
"     \"Oocyte donation for assisted reproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To minimize the risk of dissection, the authors suggest close cardiovascular monitoring in Turner patients with a dilated ascending aorta. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14329?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of Turner syndrome (gonadal dysgenesis)\", section on 'Cardiovascular anomalies in children'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14329?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of Turner syndrome (gonadal dysgenesis)\", section on 'Cardiovascular anomalies in adults'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is more common in women with Turner syndrome compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In a series of 62 patients (age range 5 to 22 years) with Turner syndrome, 30 percent were mildly hypertensive and 50 percent had an abnormal diurnal blood pressure profile as measured by 24-hour ambulatory blood pressure monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/42\">",
"     42",
"    </a>",
"    ]. Neither the presence of renal or cardiac abnormalities nor treatment with growth hormone or estrogen had an effect on blood pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other cardiovascular anomalies have been reported in patients with Turner syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 85 patients, abnormalities included elongation of the transverse aortic arch (49 percent), aberrant right subclavian artery (8 percent), persistent left superior vena cava (13 percent), and partial anomalous pulmonary venous return (13 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/44\">",
"       44",
"      </a>",
"      ]. Neck webbing and increased thoracic anterior-to-posterior diameters were strong predictors for these cardiovascular anomalies.",
"     </li>",
"     <li>",
"      A prolonged QT interval has been reported in some series, including in young children with Turner syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/45-48\">",
"       45-48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 93 women with Turner syndrome, 11 with 46,XX primary amenorrhea and 25 normal controls, mean carotid intima-media thickness was increased to a similar degree in the two hypogonadal groups, suggesting a primary role for estrogen deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/49\">",
"       49",
"      </a>",
"      ]. However, the patients with Turner syndrome had additional abnormalities when compared with both the 46,XX primary amenorrhea and control groups, including increased common carotid, aortic root, and brachial artery diameters, suggesting additional genetic factors that contribute to their vasculopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis and fractures have been reported to be common in women with Turner syndrome, thought to be due to both ovarian failure and possibly haploinsufficiency for bone-related X-chromosome genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above.) However, in some studies, patients who receive standard estrogen therapy appear to have normal bone density when compared with age-matched healthy women. As an example, in a study of 70 adult women with Turner syndrome who underwent bone mineral density testing (DEXA), osteoporosis was diagnosed in seven (10 percent), six of whom were over age 45 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/52\">",
"     52",
"    </a>",
"    ]. None of the women with osteoporosis had ever received prolonged estrogen replacement. Fracture rates in the patients who had received estrogen therapy were no different from age-matched controls.",
"   </p>",
"   <p>",
"    Some of the osteopenia reported in Turner syndrome patients may be due to an underestimation of bone mineral density in small subjects. This was suggested in a study of 40 adult women with Turner syndrome in which osteoporosis was overdiagnosed in patients less than 150 cm tall unless bone mineral density measurements were adjusted for body size (and therefore bone size). After adjustment for body size, the prevalence of osteoporosis and fractures in the Turner syndrome patients who had been treated with estrogen was the same as age-matched controls without Turner syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the ideal controls to which Turner syndrome patients should be compared are women with ovarian failure and a normal karyotype, thereby controlling for the ovarian hormone deficiency. In a study comparing 41 women with Turner syndrome to a control group of 35 karyotypically normal women with premature ovarian failure, a selective reduction in cortical (forearm) bone mineral density was seen in the Turner syndrome patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/54\">",
"     54",
"    </a>",
"    ]. This difference persisted after adjustment for height, age of puberty, lifetime estrogen exposure, and serum 25-hydroxyvitamin D concentrations.",
"   </p>",
"   <p>",
"    Thus, there appears to be a selective reduction in bone mineral density in women with Turner syndrome that is independent of ovarian hormone exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Risk of malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with Turner syndrome whose karyotype includes a Y chromosome (such as",
"    <span class=\"nowrap\">",
"     45,X/46,XY",
"    </span>",
"    mosaicism), are at increased risk for gonadoblastoma, a neoplasm that occurs in dysgenetic gonads [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/55\">",
"     55",
"    </a>",
"    ]. In a population-based study that included 3425 women with Turner syndrome followed for a mean of 17 years, five women, all with Y-chromosome material, developed gonadoblastoma (cumulative risk 7.9 percent by age 25 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Y chromosome mosaicism'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/40/5770?source=see_link&amp;anchor=H25#H25\">",
"     \"Anatomy and pathology of testicular tumors\", section on 'Mixed GCT and SCST'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients may also be at increased risk for other tumors. In the population-based study noted above, the overall risk of cancer was not increased, but site-specific risks were increased for meningioma, childhood brain tumors, bladder, and uterine cancer (but not breast cancer), when compared with the general population. However, the clinical importance of this finding is unclear, as the number of cases was small.",
"   </p>",
"   <p>",
"    The risk of breast cancer has been a concern in women with Turner syndrome who receive long-term postmenopausal hormone therapy, but no excess risk has been reported thus far. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14329?source=see_link\">",
"     \"Management of Turner syndrome (gonadal dysgenesis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ocular abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular abnormalities are common among patients with Turner syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/57\">",
"     57",
"    </a>",
"    ]. Amblyopia, strabismus, ptosis, hypertelorism, epicanthus, farsightedness, and red-green color blindness have been noted in small case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Keratoconus, glaucoma, anterior lenticonus, cataracts, retinal vascular changes, and retinal detachment have been noted in case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/57,60\">",
"     57,60",
"    </a>",
"    ]. Neovascular changes of the retina can occur in response to growth postmenopausal hormone therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/61\">",
"     61",
"    </a>",
"    ], in the absence of exogenous growth hormone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/57\">",
"     57",
"    </a>",
"    ], and in association with type 2 diabetes mellitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Turner syndrome is associated with an increased risk of autoimmune disorders, most importantly, hypothyroidism (Hashimoto&rsquo;s thyroiditis), celiac disease, and inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/21,62,63\">",
"     21,62,63",
"    </a>",
"    ]. The best evidence comes from a prospective study of autoimmune diagnoses in women with Turner syndrome (TS) (n = 244) or karyotypically normal (46,XX) primary ovarian insufficiency (POI; ovarian failure) (n = 457), compared with normative data for the US population of women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/21\">",
"     21",
"    </a>",
"    ]. Autoimmune hypothyroidism (Hashimoto&rsquo;s thyroiditis) occurred in 37 percent of women with TS compared with 15 percent in women with POI; the prevalence in both groups was higher than that in normal cycling women (5.8 percent).",
"   </p>",
"   <p>",
"    The prevalence of both inflammatory bowel disease and celiac disease were significantly increased in TS (4 and 2.7 percent, respectively), but not in POI. No other autoimmune diagnosis, including type 1 diabetes or hyperthyroidism due to Graves&rsquo; disease was increased.",
"   </p>",
"   <p>",
"    In a second study of 389 girls with Turner syndrome screened with IgA antigliadin antibodies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiendomysial antibodies, 25 (6.4 percent) had celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/64\">",
"     64",
"    </a>",
"    ]. Of these, 10 had typical symptoms, eight had atypical symptoms, and seven had no symptoms. The prevalence of celiac disease in the general population is estimated to be 1 in 184 (0.54 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Metabolic issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Turner syndrome are at risk for metabolic disorders. Insulin resistance, as measured by euglycemic clamp studies, is an early metabolic defect in girls with Turner syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/65\">",
"     65",
"    </a>",
"    ]. Abdominal adiposity is lower and glucose tolerance better in growth hormone-treated girls with Turner syndrome compared with untreated girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/66\">",
"     66",
"    </a>",
"    ]. In addition, an increased frequency of central obesity, insulin resistance, type 2 diabetes, and dyslipidemia has been reported in adult women with Turner syndrome when compared with women without Turner syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Turner syndrome may be apparent at birth due to the presence of classic anatomic abnormalities such as lymphedema. In other patients, the major presenting feature may be growth failure in childhood, failure to enter or complete puberty, or even secondary amenorrhea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/2/36903?source=see_link\">",
"     \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Karyotype analysis should be performed to confirm the diagnosis in any patient suspected to have Turner syndrome. Analysis of buccal smears for nuclear heterochromatin (Barr bodies) is an inaccurate and outmoded test and should not be used diagnostically.",
"   </p>",
"   <p>",
"    A good karyotype includes review of at least 30 cells. A positive test provides a diagnosis. There are case reports of girls strongly suspected of having Turner syndrome on clinical grounds who have a normal peripheral blood lymphocyte karyotype (46,XX) but a 45,X karyotype on analysis of skin fibroblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/67\">",
"     67",
"    </a>",
"    ]. This may be due to abnormal cell lines dying out with age in the bone marrow, leaving the normal cell line in the peripheral blood. Consequently, patients with typical clinical features of Turner syndrome and a normal peripheral blood lymphocyte karyotype should have karyotyping of a second tissue such as the skin. The distribution of mosaicism may also be different in different tissues in the same patient.",
"   </p>",
"   <p>",
"    Karyotype analysis is a cumbersome and expensive test for the diagnosis of Turner syndrome. Unfortunately, many girls, in spite of their short stature, are not diagnosed until after age 10, and therefore do not receive early treatment with growth hormone. An easier test that would allow widespread screening and earlier diagnosis would be ideal. A quantitative, pyrosequencing test based upon 18 X chromosome and one Y chromosome SNPs (single nucleotide polymorphisms) has been studied that appears to be both sensitive and specific for Turner syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. The ultimate clinical utility of this test remains unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Y chromosome mosaicism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient with Turner syndrome who presents with virilization should also be studied for Y-chromosome mosaicism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/70\">",
"     70",
"    </a>",
"    ]. The presence of an entire Y-chromosome or identifiable pericentromeric fragments of it are associated with an increased risk of gonadoblastoma (germ-cell tumor). Routine molecular searches for Y-derived DNA, including the SRY gene (sex-determining region of the Y-chromosome), are not useful because the gene that increases the risk of gonadoblastoma has not been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylactic removal of the gonad is usually indicated in patients with Y-chromosome mosaicism, even though it may look like a streak gonad [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/8\">",
"     8",
"    </a>",
"    ]. Hysterectomy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended, because donor-ovum transplantation has enabled some women with Turner syndrome to become pregnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/72\">",
"     72",
"    </a>",
"    ]. These recommendations do not apply to patients with a 45,X karyotype in whom the streak gonads do not need to be explored, examined by biopsy, or removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Turner syndrome do not have growth hormone deficiency. Thus, testing growth hormone secretion is not indicated despite the presence of short stature. There are, however, some other tests that should be performed (",
"    <a class=\"graphic graphic_table graphicRef50455 graphicRef63261 graphicRef73981 \" href=\"mobipreview.htm?11/20/11598\">",
"     table 2A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is an increased risk of hypothyroidism",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      goiter due to chronic autoimmune thyroiditis in Turner syndrome. As a result, serum thyrotropin (TSH) should be measured initially and once yearly thereafter.",
"     </li>",
"     <li>",
"      Infants and children found to have Turner syndrome should be studied by echocardiography or magnetic resonance imaging to detect cardiovascular anomalies such as coarctation of the aorta or a bicuspid aortic valve, both of which are the most common causes of morbidity and mortality in this disorder (",
"      <a class=\"graphic graphic_algorithm graphicRef69744 \" href=\"mobipreview.htm?21/44/22222\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Blood glucose, serum creatinine, and urinalysis should be done initially and once yearly thereafter because of the risks of diabetes mellitus and chronic renal disease, respectively.",
"     </li>",
"     <li>",
"      Patients should undergo hearing testing and ophthalmologic exams as outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef50455 graphicRef63261 graphicRef73981 \" href=\"mobipreview.htm?11/20/11598\">",
"       table 2A-C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Psychologic and educational issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychologic assessment should be part of the initial evaluation and ongoing management plan for each child with Turner syndrome. Assessment of intellectual skills, learning skills, motor skills, and social maturity is recommended",
"    <strong>",
"     before",
"    </strong>",
"    enrollment in preschool programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/75\">",
"     75",
"    </a>",
"    ]. Intelligence is usually",
"    <strong>",
"     normal",
"    </strong>",
"    , except in the rare patient with a tiny X-ring chromosome, who may have severe mental retardation because tiny X-ring chromosomes fail to undergo X inactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most individuals with Turner syndrome have normal intelligence, there are increased risks for selective impairment in nonverbal skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/2,78\">",
"     2,78",
"    </a>",
"    ]. This may include deficits in social cognition, difficulty with nonverbal problem-solving tasks such as mathematics, psychomotor deficits, such as clumsiness, and problems with visual-spatial organization, which may cause difficulty driving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/12\">",
"     12",
"    </a>",
"    ]. There is also an increased risk of attention deficit disorder. By contrast, verbal skills are often strong. These neurodevelopmental abnormalities may result from the X-chromosome monosomy or from sex steroid deficiencies due to gonadal dysgenesis.",
"   </p>",
"   <p>",
"    Imprinting by material from the paternal X-chromosome was suggested in one report, implying that social functioning is influenced by an imprinted gene on the X-chromosome that is switched off when this gene is inherited from the mother [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33449/abstract/79\">",
"     79",
"    </a>",
"    ]. The existence of such a gene may partly explain the male-female differences in social cognition; it does not, however, provide an explanation for all psychological findings in Turner syndrome. Such an explanation would most likely involve an interplay between many genes and interacting environmental factors.",
"   </p>",
"   <p>",
"    As these young women make the transition to independent living, counselors should stress that their learning difficulties do not disappear with age. Specific strategies to prevent or minimize learning disabilities in individuals with Turner syndrome, including the effects of gonadal hormone replacement, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14329?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of Turner syndrome (gonadal dysgenesis)\", section on 'Cognitive function and learning disabilities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     FAMILY SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information for caregivers and patients can be obtained from:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Turner Syndrome Society of the United States",
"    <br/>",
"    &nbsp; &nbsp;Tel: 1-800-365-9944",
"    <br/>",
"    &nbsp;&nbsp;&nbsp;&nbsp;",
"    <a class=\"external\" href=\"file://www.turnersyndrome.org/\">",
"     www.turnersyndrome.org",
"    </a>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Turner Syndrome Society of Canada",
"    <br/>",
"    &nbsp; &nbsp;Tel: 1-800-465-6744",
"    <br/>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"    <a class=\"external\" href=\"file://www.turnersyndrome.ca/\">",
"     www.TurnerSyndrome.ca",
"    </a>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Turner Syndrome Society of UK",
"    <br/>",
"    &nbsp; &nbsp;Tel: +44(0)1389-380385",
"    <br/>",
"    &nbsp;&nbsp;&nbsp;&nbsp;",
"    <a class=\"external\" href=\"file://www.tss.org.uk/\">",
"     www.tss.org.uk/",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/20/32065?source=see_link\">",
"       \"Patient information: Turner syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615191\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Turner syndrome (TS), the most common sex-chromosome abnormality (loss of part or all of an X-chromosome), affects approximately 1 in every 2500 live born female newborns worldwide. It is a disorder of growth and development that is almost always associated with short stature and primary amenorrhea due to early ovarian failure. Other physical features are described in the table (",
"      <a class=\"graphic graphic_table graphicRef60006 \" href=\"mobipreview.htm?12/38/12910\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Girls/women",
"      </span>",
"      with Turner syndrome whose karyotype includes a Y chromosome (such as",
"      <span class=\"nowrap\">",
"       45,X/46,XY",
"      </span>",
"      mosaicism) are at increased risk for gonadoblastoma, a neoplasm that occurs in dysgenetic gonads. These patients require gonadectomy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Risk of malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Turner syndrome are at increased risk for cardiovascular morbidity, presumably due to their risk of cardiovascular malformations, renal abnormalities, and hypertension. Abnormalities include coarctation, aortic valvular disease, and aortic dissection (a particular concern during pregnancy). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cardiovascular disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Aortic dissection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteoporosis and fractures are common in women with Turner syndrome, thought to be due to both ovarian failure and possibly haploinsufficiency for bone-related X-chromosome genes. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Osteoporosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Girls with Turner syndrome are more likely than girls without Turner syndrome to develop abdominal obesity, insulin resistance, and type 2 diabetes; all may improve with growth hormone therapy. Women with Turner syndrome are at increased risk for autoimmune endocrinopathies, most importantly, hypothyroidism. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Metabolic issues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Autoimmune disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Turner syndrome is sometimes made at birth in the patient with classic physical features such as webbed neck and congenital lymphedema. Other patients are diagnosed later, when they present with either growth failure in childhood, failure to enter or complete puberty, or early ovarian failure. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/1\">",
"      Turner, HH. A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology 1938; 28:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/2\">",
"      Bondy CA, Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007; 92:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/3\">",
"      Gunther DF, Eugster E, Zagar AJ, et al. Ascertainment bias in Turner syndrome: new insights from girls who were diagnosed incidentally in prenatal life. Pediatrics 2004; 114:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/4\">",
"      Mathur A, Stekol L, Schatz D, et al. The parental origin of the single X chromosome in Turner syndrome: lack of correlation with parental age or clinical phenotype. Am J Hum Genet 1991; 48:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/5\">",
"      FERGUSON-SMITH MA. KARYOTYPE-PHENOTYPE CORRELATIONS IN GONADAL DYSGENESIS AND THEIR BEARING ON THE PATHOGENESIS OF MALFORMATIONS. J Med Genet 1965; 2:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/6\">",
"      Simpson JL. Gonadal dysgenesis and abnormalities of the human sex chromosomes: current status of phenotypic-karyotypic correlations. Birth Defects Orig Artic Ser 1975; 11:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/7\">",
"      Held KR, Kerber S, Kaminsky E, et al. Mosaicism in 45,X Turner syndrome: does survival in early pregnancy depend on the presence of two sex chromosomes? Hum Genet 1992; 88:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/8\">",
"      Binder G, Koch A, Wajs E, Ranke MB. Nested polymerase chain reaction study of 53 cases with Turner's syndrome: is cytogenetically undetected Y mosaicism common? J Clin Endocrinol Metab 1995; 80:3532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/9\">",
"      Rao E, Weiss B, Fukami M, et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 1997; 16:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/10\">",
"      Ross JL, Scott C Jr, Marttila P, et al. Phenotypes Associated with SHOX Deficiency. J Clin Endocrinol Metab 2001; 86:5674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/11\">",
"      Ross JL, Kowal K, Quigley CA, et al. The phenotype of short stature homeobox gene (SHOX) deficiency in childhood: contrasting children with Leri-Weill dyschondrosteosis and Turner syndrome. J Pediatr 2005; 147:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/12\">",
"      Sybert VP, McCauley E. Turner's syndrome. N Engl J Med 2004; 351:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/13\">",
"      Wyss D, DeLozier CD, Daniell J, Engel E. Structural anomalies of the X chromosome: personal observation and review of non-mosaic cases. Clin Genet 1982; 21:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/14\">",
"      S&auml;vendahl L, Davenport ML. Delayed diagnoses of Turner's syndrome: proposed guidelines for change. J Pediatr 2000; 137:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/15\">",
"      Ranke MB, Pfl&uuml;ger H, Rosendahl W, et al. Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur J Pediatr 1983; 141:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/16\">",
"      Brook CG, M&uuml;rset G, Zachmann M, Prader A. Growth in children with 45,XO Turner's syndrome. Arch Dis Child 1974; 49:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/17\">",
"      Sylv&eacute;n L, Hagenfeldt K, Br&ouml;ndum-Nielsen K, von Schoultz B. Middle-aged women with Turner's syndrome. Medical status, hormonal treatment and social life. Acta Endocrinol (Copenh) 1991; 125:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/18\">",
"      Freriks K, Timmermans J, Beerendonk CC, et al. Standardized multidisciplinary evaluation yields significant previously undiagnosed morbidity in adult women with Turner syndrome. J Clin Endocrinol Metab 2011; 96:E1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/19\">",
"      Elsheikh M, Hodgson HJ, Wass JA, Conway GS. Hormone replacement therapy may improve hepatic function in women with Turner's syndrome. Clin Endocrinol (Oxf) 2001; 55:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/20\">",
"      El-Mansoury M, Berntorp K, Bryman I, et al. Elevated liver enzymes in Turner syndrome during a 5-year follow-up study. Clin Endocrinol (Oxf) 2008; 68:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/21\">",
"      Bakalov VK, Gutin L, Cheng CM, et al. Autoimmune disorders in women with turner syndrome and women with karyotypically normal primary ovarian insufficiency. J Autoimmun 2012; 38:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/22\">",
"      Chiovato L, Larizza D, Bendinelli G, et al. Autoimmune hypothyroidism and hyperthyroidism in patients with Turner's syndrome. Eur J Endocrinol 1996; 134:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/23\">",
"      Ostberg JE, Conway GS. Adulthood in women with Turner syndrome. Horm Res 2003; 59:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/24\">",
"      Pasquino AM, Passeri F, Pucarelli I, et al. Spontaneous pubertal development in Turner's syndrome. Italian Study Group for Turner's Syndrome. J Clin Endocrinol Metab 1997; 82:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/25\">",
"      Hadnott TN, Gould HN, Gharib AM, Bondy CA. Outcomes of spontaneous and assisted pregnancies in Turner syndrome: the U.S. National Institutes of Health experience. Fertil Steril 2011; 95:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/26\">",
"      Singh RP, Carr DH. The anatomy and histology of XO human embryos and fetuses. Anat Rec 1966; 155:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/27\">",
"      Massarano AA, Adams JA, Preece MA, Brook CG. Ovarian ultrasound appearances in Turner syndrome. J Pediatr 1989; 114:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/28\">",
"      King CR, Magenis E, Bennett S. Pregnancy and the Turner syndrome. Obstet Gynecol 1978; 52:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/29\">",
"      Reyes FI, Koh KS, Faiman C. Fertility in women with gonadal dysgenesis. Am J Obstet Gynecol 1976; 126:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/30\">",
"      Chang P, Tsau YK, Tsai WY, et al. Renal malformations in children with Turner's syndrome. J Formos Med Assoc 2000; 99:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/31\">",
"      Flynn MT, Ekstrom L, De Arce M, et al. Prevalence of renal malformation in Turner syndrome. Pediatr Nephrol 1996; 10:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/32\">",
"      Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol 1998; 51:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/33\">",
"      G&oslash;tzsche CO, Krag-Olsen B, Nielsen J, et al. Prevalence of cardiovascular malformations and association with karyotypes in Turner's syndrome. Arch Dis Child 1994; 71:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/34\">",
"      Elsheikh M, Casadei B, Conway GS, Wass JA. Hypertension is a major risk factor for aortic root dilatation in women with Turner's syndrome. Clin Endocrinol (Oxf) 2001; 54:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/35\">",
"      Sachdev V, Matura LA, Sidenko S, et al. Aortic valve disease in Turner syndrome. J Am Coll Cardiol 2008; 51:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/36\">",
"      Ilyas M, Chu C, Ettles D, et al. Evaluation by magnetic resonance imaging of aortic dilatation and coarctation in adult Turner syndrome patients. Clin Endocrinol (Oxf) 2006; 65:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/37\">",
"      Lin AE, Lippe B, Rosenfeld RG. Further delineation of aortic dilation, dissection, and rupture in patients with Turner syndrome. Pediatrics 1998; 102:e12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/38\">",
"      Matura LA, Ho VB, Rosing DR, Bondy CA. Aortic dilatation and dissection in Turner syndrome. Circulation 2007; 116:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/39\">",
"      Carlson M, Airhart N, Lopez L, Silberbach M. Moderate aortic enlargement and bicuspid aortic valve are associated with aortic dissection in Turner syndrome: report of the international turner syndrome aortic dissection registry. Circulation 2012; 126:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/40\">",
"      Karnis MF, Zimon AE, Lalwani SI, et al. Risk of death in pregnancy achieved through oocyte donation in patients with Turner syndrome: a national survey. Fertil Steril 2003; 80:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/41\">",
"      Practice Committee of the American Society for Reproductive Medicine. Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome. Fertil Steril 2006; 86:S127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/42\">",
"      Nathwani NC, Unwin R, Brook CG, Hindmarsh PC. The influence of renal and cardiovascular abnormalities on blood pressure in Turner syndrome. Clin Endocrinol (Oxf) 2000; 52:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/43\">",
"      Landin-Wilhelmsen K, Bryman I, Wilhelmsen L. Cardiac malformations and hypertension, but not metabolic risk factors, are common in Turner syndrome. J Clin Endocrinol Metab 2001; 86:4166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/44\">",
"      Ho VB, Bakalov VK, Cooley M, et al. Major vascular anomalies in Turner syndrome: prevalence and magnetic resonance angiographic features. Circulation 2004; 110:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/45\">",
"      Bondy CA, Van PL, Bakalov VK, et al. Prolongation of the cardiac QTc interval in Turner syndrome. Medicine (Baltimore) 2006; 85:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/46\">",
"      Bondy CA, Bakalov VK. Investigation of cardiac status and bone mineral density in Turner syndrome. Growth Horm IGF Res 2006; 16 Suppl A:S103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/47\">",
"      Bondy CA, Ceniceros I, Van PL, et al. Prolonged rate-corrected QT interval and other electrocardiogram abnormalities in girls with Turner syndrome. Pediatrics 2006; 118:e1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/48\">",
"      Dalla Pozza R, Bechtold S, Urschel S, et al. QTc interval prolongation in children with Turner syndrome: the results of exercise testing and 24-h ECG. Eur J Pediatr 2009; 168:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/49\">",
"      Ostberg JE, Donald AE, Halcox JP, et al. Vasculopathy in Turner syndrome: arterial dilatation and intimal thickening without endothelial dysfunction. J Clin Endocrinol Metab 2005; 90:5161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/50\">",
"      Rubin K. Turner syndrome and osteoporosis: mechanisms and prognosis. Pediatrics 1998; 102:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/51\">",
"      Gravholt CH, Vestergaard P, Hermann AP, et al. Increased fracture rates in Turner's syndrome: a nationwide questionnaire survey. Clin Endocrinol (Oxf) 2003; 59:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/52\">",
"      Landin-Wilhelmsen K, Bryman I, Windh M, Wilhelmsen L. Osteoporosis and fractures in Turner syndrome-importance of growth promoting and oestrogen therapy. Clin Endocrinol (Oxf) 1999; 51:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/53\">",
"      Bakalov VK, Chen ML, Baron J, et al. Bone mineral density and fractures in Turner syndrome. Am J Med 2003; 115:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/54\">",
"      Bakalov VK, Axelrod L, Baron J, et al. Selective reduction in cortical bone mineral density in turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab 2003; 88:5717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/55\">",
"      Gravholt CH, Fedder J, Naeraa RW, M&uuml;ller J. Occurrence of gonadoblastoma in females with Turner syndrome and Y chromosome material: a population study. J Clin Endocrinol Metab 2000; 85:3199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/56\">",
"      Schoemaker MJ, Swerdlow AJ, Higgins CD, et al. Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study. Lancet Oncol 2008; 9:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/57\">",
"      Denniston A. Turner's syndrome. Lancet 2001; 358:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/58\">",
"      Chrousos GA, Ross JL, Chrousos G, et al. Ocular findings in Turner syndrome. A prospective study. Ophthalmology 1984; 91:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/59\">",
"      Adhikary HP. Ocular manifestations of Turner's syndrome. Trans Ophthalmol Soc U K 1981; 101 (Pt 4):395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/60\">",
"      Mason JO 3rd, Tasman W. Turner's syndrome associated with bilateral retinal detachments. Am J Ophthalmol 1996; 122:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/61\">",
"      Koller EA, Green L, Gertner JM, et al. Retinal changes mimicking diabetic retinopathy in two nondiabetic, growth hormone-treated patients. J Clin Endocrinol Metab 1998; 83:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/62\">",
"      Elsheikh M, Wass JA, Conway GS. Autoimmune thyroid syndrome in women with Turner's syndrome--the association with karyotype. Clin Endocrinol (Oxf) 2001; 55:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/63\">",
"      El-Mansoury M, Bryman I, Berntorp K, et al. Hypothyroidism is common in turner syndrome: results of a five-year follow-up. J Clin Endocrinol Metab 2005; 90:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/64\">",
"      Bonamico M, Pasquino AM, Mariani P, et al. Prevalence and clinical picture of celiac disease in Turner syndrome. J Clin Endocrinol Metab 2002; 87:5495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/65\">",
"      Caprio S, Boulware S, Diamond M, et al. Insulin resistance: an early metabolic defect of Turner's syndrome. J Clin Endocrinol Metab 1991; 72:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/66\">",
"      Wooten N, Bakalov VK, Hill S, Bondy CA. Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab 2008; 93:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/67\">",
"      Azcona C, Bareille P, Stanhope R. Lesson of the week: Turner's syndrome mosaicism in patients with a normal blood lymphocyte karyotype. BMJ 1999; 318:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/68\">",
"      Rivkees SA, Hager K, Hosono S, et al. A highly sensitive, high-throughput assay for the detection of Turner syndrome. J Clin Endocrinol Metab 2011; 96:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/69\">",
"      Rivkees SA. Ending the late diagnosis of Turner syndrome through a novel high-throughput assay. Pediatr Endocrinol Rev 2012; 9 Suppl 2:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/70\">",
"      Gemmill RM, Pearce-Birge L, Bixenman H, et al. Y chromosome--specific DNA sequences in Turner-syndrome mosaicism. Am J Hum Genet 1987; 41:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/71\">",
"      Tsuchiya K, Reijo R, Page DC, Disteche CM. Gonadoblastoma: molecular definition of the susceptibility region on the Y chromosome. Am J Hum Genet 1995; 57:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/72\">",
"      Navot D, Laufer N, Kopolovic J, et al. Artificially induced endometrial cycles and establishment of pregnancies in the absence of ovaries. N Engl J Med 1986; 314:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/73\">",
"      Saenger P, Wikland KA, Conway GS, et al. Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab 2001; 86:3061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/74\">",
"      Ranke MB, Saenger P. Turner's syndrome. Lancet 2001; 358:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/75\">",
"      Bender B, Puck M, Salbenblatt J, Robinson A. Cognitive development of unselected girls with complete and partial X monosomy. Pediatrics 1984; 73:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/76\">",
"      Migeon BR, Luo S, Stasiowski BA, et al. Deficient transcription of XIST from tiny ring X chromosomes in females with severe phenotypes. Proc Natl Acad Sci U S A 1993; 90:12025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/77\">",
"      Collins AL, Cockwell AE, Jacobs PA, Dennis NR. A comparison of the clinical and cytogenetic findings in nine patients with a ring (X) cell line and 16 45,X patients. J Med Genet 1994; 31:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/78\">",
"      McCauley E, Feuillan P, Kushner H, Ross JL. Psychosocial development in adolescents with Turner syndrome. J Dev Behav Pediatr 2001; 22:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33449/abstract/79\">",
"      Skuse DH, James RS, Bishop DV, et al. Evidence from Turner's syndrome of an imprinted X-linked locus affecting cognitive function. Nature 1997; 387:705.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7391 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33449=[""].join("\n");
var outline_f32_42_33449=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H615191\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ovarian failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Short stature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Renal anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Coarctation/aortic valve disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H523815943\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ocular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Metabolic issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Y chromosome mosaicism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Psychologic and educational issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      FAMILY SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H615191\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7391\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7391|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?21/44/22222\" title=\"algorithm 1\">",
"      Cardiovascular management Turner syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7391|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/21/34129\" title=\"figure 1\">",
"      Turner syndrome growth chart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7391|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/38/12910\" title=\"table 1\">",
"      Manifestations Turner syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/23/11644\" title=\"table 2A\">",
"      Treatment Turner I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/2/27691\" title=\"table 2B\">",
"      Treatment Turner II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/45/37596\" title=\"table 2C\">",
"      Treatment Turner III",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/2/36903?source=related_link\">",
"      Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14329?source=related_link\">",
"      Management of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24807?source=related_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7817?source=related_link\">",
"      Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/20/32065?source=related_link\">",
"      Patient information: Turner syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_42_33450="Primary prevention of opportunistic infections in HIV-infected patients";
var content_f32_42_33450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary prevention of opportunistic infections in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33450/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33450/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33450/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33450/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/42/33450/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/42/33450/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/42/33450/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-related immunosuppression significantly increases the risk for acquiring opportunistic infections due to bacteria, viruses, fungi, and protozoa. These opportunistic infections are a major source of morbidity and mortality in HIV-infected patients.",
"   </p>",
"   <p>",
"    Substantial advances in the prevention of opportunistic infections have been achieved. These strategies involve prophylactic antibiotics, immunizations, and public health measures. The cost effectiveness of preventing infections is variable, ranging from $16,000 per quality adjusted life-year saved for Pneumocystis carinii pneumonia to over $300,000 for cytomegalovirus (",
"    <a class=\"graphic graphic_table graphicRef72472 \" href=\"mobipreview.htm?30/4/30795\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommendations listed below largely reflect the 2009",
"    <span class=\"nowrap\">",
"     NIH/CDC/IDSA",
"    </span>",
"    Guidelines for Treatment and Prevention of Opportunistic Infections in HIV-infected Adults and Adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ]. The 2009 guidelines emphasize the primary importance of antiretroviral therapy in reconstituting the immune system to reduce the risk of opportunistic infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ]. Several new infections have been added to the 2009 guidelines as well, including hepatitis B and malaria. The prevention and treatment of these diseases are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7033?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/8/3209?source=see_link\">",
"     \"HIV and malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of prophylactic antibiotics for primary prevention of the most common opportunistic infections will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef53768 \" href=\"mobipreview.htm?12/40/12939\">",
"     table 2",
"    </a>",
"    ). Clinical manifestations and treatment of specific opportunistic infections and secondary prophylaxis are also discussed elsewhere. (See appropriate topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF OPPORTUNISTIC INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widespread use of potent antiretroviral therapy (ART) has led to a dramatic decline in the incidence of opportunistic infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/3\">",
"     3",
"    </a>",
"    ]. In a cohort of 2410 patients followed in seven centers in Switzerland in 1995-1997, the incidence of any OI decreased from 15.1 per 100 person-years in the 6 months before therapy to 7.7 in the first 3 months after starting treatment, 2.6 in the following 6 months, and 2.2 per 100 person-years between 9 and 15 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/3\">",
"     3",
"    </a>",
"    ]. In a multicenter study of more than 8500 HIV-infected patients in the United States, the rates of OIs declined from 140 per 1000 person-years of observation in 1995 to less than 20 per 1000 person-years of observation in 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/4\">",
"     4",
"    </a>",
"    ]. Similar trends have been noted in resource-limited settings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lower rates of opportunistic infections have also been associated with a marked decline in mortality. One study evaluated 31,620 HIV-infected patients to assess whether mortality differs by the specific type of AIDS-defining event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/5\">",
"     5",
"    </a>",
"    ]. During a median follow-up period of 43 months, 2880 AIDS-defining events were diagnosed in 2262 patients; 1146 patients died. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common diagnoses were esophageal candidiasis, Pneumocystis jirovecii pneumonia, and Kaposi sarcoma.",
"     </li>",
"     <li>",
"      Three categories of AIDS-defining events were identified based on the relative risk of death:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp;Severe: Non-Hodgkin's lymphoma and progressive multifocal leukoencephalopathy (HR, 7.3; 95% CI 5.55-9.48)",
"   </p>",
"   <p>",
"    &nbsp;Moderate: Cryptococcosis, cerebral toxoplasmosis, AIDS dementia complex, and disseminated Mycobacterium avium complex (HR, 2.35; 95% CI 1.8-3.1)",
"   </p>",
"   <p>",
"    &nbsp;Mild: All other OIs (HR, 1.47; 95% CI 1.08-2.0)",
"   </p>",
"   <p>",
"    These data suggest that in the era of potent ART, the risk of mortality is related to the specific AIDS-defining event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESTORATION OF CELLULAR IMMUNITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect of ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restoration of immunity secondary to effective ART can also allow the safe discontinuation of prophylaxis. However, attention still needs to be paid to the prevention of opportunistic infections among treated patients who do not attain adequate immunologic recovery, or in those who experience a decline in CD4 cell counts after initial improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect of interleukin 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two clinical trials demonstrated that although substantial CD4 cell count increases occurred with concurrent administration of interleukin-2 with ART versus ART alone, no reduction of opportunistic infections was demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PNEUMOCYSTIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis jirovecii (carinii) pneumonia remains the leading initial AIDS-defining illness and an important cause of death in patients with AIDS. In the absence of antiretroviral therapy and prophylaxis, the risk of Pneumocystis pneumonia is 40 to 50",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    in patients with a CD4 count less than 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/7\">",
"     7",
"    </a>",
"    ]. The major reasons for prophylaxis failure are a CD4 count less than 50",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and non-adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic is discussed in detail elsewhere. A brief summary is found below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2889?source=see_link\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Who is at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common risk factor for the development of PCP is a CD4 count &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and thrush [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Preventing exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis is ubiquitous in the environment. Geographic clustering of cases and typing of strains have suggested that person-to-person spread may account for some cases of",
"    <span class=\"nowrap\">",
"     transmission/",
"    </span>",
"    However, the",
"    <span class=\"nowrap\">",
"     NIH/CDC/IDSA",
"    </span>",
"    Guidelines do not recommend isolation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2,12-14\">",
"     2,12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic regimens include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    , or aerosolized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef79988 \" href=\"mobipreview.htm?23/15/23804\">",
"     table 3",
"    </a>",
"    ). We recommend TMP-SMX as a first-line agent. Dosing regimens, which include one single-strength tablet daily or one double strength tablet daily; a single strength tablet is often better tolerated but a double strength tablet is preferred when possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ]; this dose also gives cross-protection against toxoplasma infection (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Toxoplasma'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    An early trial demonstrated a significant survival advantage with primary TMP-SMX PCP prophylaxis. Subsequent trials and a large meta-analysis suggested that TMP-SMX is the most effective agent of those studied, and should be prescribed unless the patient has a history of hypersensitivity to sulfa medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/9\">",
"     9",
"    </a>",
"    ]. In the absence of antiretroviral therapy and prophylaxis, the risk of Pneumocystis is 40 to 50 percent per year in patients with a CD4 count &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    With prophylaxis, the risk of Pneumocystis declines ninefold and those who have breakthrough infections have a lower mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/7\">",
"     7",
"    </a>",
"    ]. Major reasons for prophylaxis failure are nonadherence and profound immunosuppression (CD4 count &lt;50",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TMP-SMX is also active against other potentially important pathogens including nocardia, Legionella, toxoplasma, salmonella, Streptococcus pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/15\">",
"     15",
"    </a>",
"    ], paracoccidioidomycosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/16\">",
"     16",
"    </a>",
"    ], and malaria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/17\">",
"     17",
"    </a>",
"    ]. The most commonly used dosing regimen is one single-strength tablet per day. Alternative regimens include one double-strength tablet three times per week or one double-strength tablet daily. The latter regimen also affords protection against toxoplasmosis in patients who are toxoplasma seropositive.",
"   </p>",
"   <p>",
"    Rash and other adverse events are commonly encountered with the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    . One meta-analysis involving 268 patients using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    -sulfamethoxazole for PCP prophylaxis found a beneficial effect of using a desensitization protocol over a rechallenge protocol for preventing recurrent hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of patients with drug-associated rash is discussed further elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2889?source=see_link\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    also has good activity against Pneumocystis, is well-absorbed, and is adequately distributed to the alveolar spaces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/19\">",
"     19",
"    </a>",
"    ]. This medication is a good alternative for patients who have a history of severe rash secondary to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    . For prevention of toxoplasmosis and PCP, dapsone can be combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Toxoplasma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Aerosolized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    (AP) is better tolerated than either TMP-SMX or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , but is less effective, particularly at low CD4 cell counts, and does not prevent toxoplasmosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/19\">",
"     19",
"    </a>",
"    ]. Cases of extrapulmonary Pneumocystis have been reported in association with aerosolized pentamidine because of its localized rather than systemic effect. Aerosolized pentamidine is administered 300 mg per month by Respirgard II nebulizer using six milliliters diluent delivered at 6",
"    <span class=\"nowrap\">",
"     L/minute",
"    </span>",
"    until the reservoir is dry. Some patients also require the use of a bronchodilator (eg, two puffs",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ) prior to therapy due to bronchospasm.",
"   </p>",
"   <p>",
"    Experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    (1500 mg daily) appears to have comparable efficacy to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    for PCP prophylaxis based on a large randomized trial with 1057 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/20\">",
"     20",
"    </a>",
"    ]; it is also as effective as aerosolized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/21\">",
"     21",
"    </a>",
"    ]. However, it is much more expensive than other alternatives ($770 per month compared to $6 per month for dapsone), and it must be taken with food. Other less commonly used alternative regimens are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2889?source=see_link&amp;anchor=H5#H5\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\", section on 'Regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In pregnant women, we suggest that systemic prophylaxis be avoided during the first trimester and prefer using aerosolized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    during this time. Some data suggest birth defects may occur in association with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    exposure in the first trimester, although the risk is low and possibly reversed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In the second and third trimester, we recommend TMP-SMX as first line prophylaxis for Pneumocystis;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    is an alternative agent.",
"   </p>",
"   <p>",
"    In patients with a CD4 count &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    who are seropositive for Toxoplasma, we suggest the use of prophylactic regimens that will also protect against reactivation of this infection. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Toxoplasma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Discontinuation of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who experience immune reconstitution on ART with a rise in CD4 cell count above 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for more than three months can usually safely discontinue PCP prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2889?source=see_link&amp;anchor=H25#H25\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\", section on 'Discontinuation of prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylaxis should be reintroduced if the CD4 count decreases to &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TOXOPLASMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In AIDS patients, toxoplasmosis is associated with cerebral abscesses and severe morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Who is at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should be screened for toxoplasma at the time of their HIV diagnosis. The risk of toxoplasmosis is 33",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    in a seropositive patient with a CD4 count less than 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Approximately 75 percent of cases occur in patients with a CD4 cell count below",
"    <span class=\"nowrap\">",
"     50/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Preventing exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    vast majority of patients have evidence of past exposure to toxoplasma; however, patients who are seronegative should be counseled to avoid eating undercooked meats (eg, lamb, beef, pork) and to use gloves or use hand hygiene when cleaning cat litter boxes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for primary prophylaxis include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    . We recommend TMPS-SMX as a first-line agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Trimethoprim-sulfamethoxazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred agent is TMP-SMX although there are no independent prospective trials of this agent for toxoplasmosis prophylaxis.",
"   </p>",
"   <p>",
"    Most data on the efficacy of prophylaxis for toxoplasmosis have emerged from retrospective analyses of this drug in PCP prophylaxis trials, which consistently show benefit in preventing toxoplasmosis as well. This can be illustrated by the findings from five studies with a total of 1400 participants that compared TMP-SMX with aerosolized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    for the prevention of Pneumocystis infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/15,29-31\">",
"     15,29-31",
"    </a>",
"    ]. The rate of toxoplasmosis was less than 1 percent for TMP-SMX recipients compared to 3 to 12 percent in controls.",
"   </p>",
"   <p>",
"    The optimal dose is not clear; most trials have been conducted with one double-strength tablet per day, which is the preferred regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2,30,32\">",
"     2,30,32",
"    </a>",
"    ]. Alternative dosing regimens include one double-strength tablet every other day or one single-strength tablet per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/32\">",
"     32",
"    </a>",
"    ]. Due to a high incidence of rash in HIV-infected patients taking TMP-SMX, alternative regimens often need to be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Dapsone-pyrimethamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three randomized clinical trials examined whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    are effective as prophylaxis for both Pneumocystis and toxoplasmosis infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. All three demonstrated efficacy, although the prophylactic regimens varied in frequency and dose. Study regimens have included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      , 50 mg orally once daily plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      , 50 mg orally per week plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      calcium, 25 mg orally per week",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      , 200 mg orally per week plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      , 75 mg orally per week plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      calcium, 25 mg",
"      <span class=\"nowrap\">",
"       orally/week.",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      , 100 mg orally plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      , 50 mg orally, both twice weekly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Concomitant administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    helps to ameliorate the bone marrow suppressive actions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Atovaquone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"     Atovaquone",
"    </a>",
"    has in vitro activity against the cysts of Toxoplasma gondii and has been used as salvage therapy for cerebral toxoplasmosis in patients intolerant of first line regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, there have been no adequately powered studies of the use of atovaquone for the primary prevention of toxoplasmosis in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One trial that compared the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    in the primary prevention of Pneumocystis infection also tried to examine whether atovaquone was effective in preventing toxoplasmosis in a post-hoc analysis. However, no conclusions regarding efficacy could be made because of the low numbers of patients who were toxoplasma seropositive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/20\">",
"     20",
"    </a>",
"    ]. If a clinical decision is made to use this particular agent because of intolerance or toxicity of other preferred regimens, the recommended dose is 1500 mg daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of alternative prophylactic regimens have shown that monotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    is not beneficial;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    is associated with an unacceptably high rate of diarrhea and rash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Discontinuation of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prophylaxis may be discontinued when HAART therapy is associated with an increase in CD4 cell count to",
"    <span class=\"nowrap\">",
"     &gt;200/microL",
"    </span>",
"    for more than three months. In one study of 199 patients, discontinuation of primary prophylaxis resulted in no cases of either toxoplasma encephalitis or PCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Discontinuation of secondary prophylaxis is recommended when the CD4 count is &gt;200",
"    <span class=\"nowrap\">",
"     cells/mL",
"    </span>",
"    x 3 months; resumption of prophylaxis should occur if the CD4 count declines to the range of 100 to 200",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This issue is also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33129?source=see_link&amp;anchor=H29#H29\">",
"     \"Toxoplasmosis in HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MYCOBACTERIUM AVIUM COMPLEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated Mycobacterium avium complex infection is a significant contributing factor to morbidity and mortality in late-stage AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38777?source=see_link\">",
"     \"Mycobacterium avium complex (MAC) infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Who is at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS in the absence of HAART is approximately 20 to 40 percent in patients with CD4 counts less than 50",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38777?source=see_link\">",
"     \"Mycobacterium avium complex (MAC) infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Preventing exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAC is ubiquitous in the environment (food, water); no specific recommendations can be made on avoidance of exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prophylaxis against MAC infection should be given to all HIV-infected patients with a CD4 cell count &lt;50",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ]. The CDC, NIH, and HIV MA guidelines recommend either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    as preferred agents for MAC prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ]. However, we recommend azithromycin as the preferred first-line agent for prophylaxis due to ease of dosing and a decrease risk of drug interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If macrolides cannot be tolerated, an alternate agent is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ; however, use of this drug is complicated by potential drug interactions with multiple other agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/43\">",
"     43",
"    </a>",
"    ] and macrolides have superior efficacy for this indication, as discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. An additional clinical benefit of the macrolides, compared to rifabutin, is their effectiveness in reducing the rates of bacterial infection, such as pneumonitis and sinusitis.",
"   </p>",
"   <p>",
"    Before prophylaxis with macrolides is initiated, blood cultures for MAC isolation should be drawn if there is any suspicion of clinical disease. Cultures of respiratory and stool specimens for MAC colonization are not recommended. In patients initiating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    , a chest x-ray should be obtained to rule out active tuberculosis, since monotherapy with this medication would lead to resistance.",
"   </p>",
"   <p>",
"    Clinical trial data with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Rifabutin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two placebo-controlled trials in the pre-HAART era evaluated 1130 patients with CD4 cell counts below",
"    <span class=\"nowrap\">",
"     200/microL.",
"    </span>",
"    The frequency of MAC bacteremia at a median of 270 days was significantly reduced in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    prophylaxis (9 versus 18 percent with placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, caution regarding the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    should be exercised in light of known drug interactions with various protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Azithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized, placebo controlled trial comparing once weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1200 mg), daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    (300",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    to combination azithromycin and rifabutin was conducted in patients with CD4 counts less than 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/45\">",
"     45",
"    </a>",
"    ]. The incidence of MAC infection at one year in the three groups was 7.6, 15.3 and 2.8 percent, respectively.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    resistant MAC was identified in 2 of 18 breakthrough isolates (11 percent) on azithromycin and in none in the combination arm. No",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    resistant isolates were identified. Dose-limiting toxicity was highest in the combination arm than with azithromycin alone (hazard ratio, 1.67). Azithromycin is associated mainly with gastrointestinal disturbance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional benefit of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    -containing prophylaxis regimen was observed in the primary prevention of Pneumocystis carinii (P. jirovecii) pneumonia. Patients receiving azithromycin alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    had a 45 percent reduction in the risk of developing a first episode of pneumonia. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Pneumocystis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Clarithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    (500 mg twice daily) was compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    (300 mg daily) and to the combination of clarithromycin and rifabutin in patients with CD4 counts less than 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/48\">",
"     48",
"    </a>",
"    ]. The cumulative incidence of disseminated MAC at one year in the intent-to-treat analysis was highest for the rifabutin arm. The combination arm offered no increased protection compared to the macrolide alone arm and was also associated with more toxicity.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    is associated with gastrointestinal disturbance and a metallic taste. It also has a number of significant drug interactions, including boosted protease inhibitors, which increase clarithromycin levels. In patients taking PIs, clarithromycin dosing may need to be decreased in the setting of renal insufficiency. In patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , the dose of clarithromycin should be reduced by 50 percent, regardless of creatinine clearance, due to a risk of QTc prolongation; use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is preferred in these patients.",
"   </p>",
"   <p>",
"    Drug interactions also occur between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and NNRTIs that are inducers of CYP 3A4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    2B6 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ). These NNRTIs can decrease clarithromycin serum levels and increase its active metabolite, 14-OH-clarithromycin, which appears to have reduced activity against Mycobacterium avium complex. When drug interactions are a concern,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is the preferred agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/8/12421?source=see_link\">",
"     \"Clarithromycin: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Susceptibility testing identified",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    resistant MAC (MIC &gt;32",
"    <span class=\"nowrap\">",
"     microgram/mL)",
"    </span>",
"    in 29 percent of the clarithromycin failures and 25 percent of the breakthroughs in the combination arm.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     Rifabutin",
"    </a>",
"    resistance (MIC &gt;2.0",
"    <span class=\"nowrap\">",
"     microgram/mL)",
"    </span>",
"    was identified in two isolates, one from a patient receiving rifabutin and one from a patient receiving clarithromycin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Evaluation prior to prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before prophylaxis with macrolides is initiated, blood cultures for MAC isolation should be drawn if there is any suspicion of clinical disease. Cultures of respiratory and stool specimens for MAC colonization are not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ]. In patients initiating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    , a chest x-ray should be obtained to rule out active tuberculosis, since monotherapy with this medication would lead to resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Discontinuation of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prophylaxis may be discontinued when HAART is associated with an increase in CD4 cell count to",
"    <span class=\"nowrap\">",
"     &gt;100/microL",
"    </span>",
"    for more than three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized clinical trials confirm the safety of this approach as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, multicenter, double-blind trial compared continuing or stopping",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      prophylaxis in 520 AIDS patients whose CD4 counts had risen to",
"      <span class=\"nowrap\">",
"       &gt;100/microL",
"      </span>",
"      on two consecutive determinations in response to HAART [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/52\">",
"       52",
"      </a>",
"      ]. No patients in either group developed MAC infection during a median of 12 months of follow-up.",
"     </li>",
"     <li>",
"      In another study (ACTG 362), 643 HIV infected subjects, whose CD4 cell counts rose from less than",
"      <span class=\"nowrap\">",
"       50/microL",
"      </span>",
"      to above",
"      <span class=\"nowrap\">",
"       100/microL,",
"      </span>",
"      were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (1200 mg once per week) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/47\">",
"       47",
"      </a>",
"      ]. After a median follow-up of 16 months, two cases of MAC disease localized to the spine developed in the placebo group compared to no cases in those randomized to azithromycin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Primary prophylaxis should be reintroduced if the CD4 count decreases to &le;50",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     HISTOPLASMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histoplasmosis is the most prevalent endemic mycosis in the United States, especially the Ohio and Mississippi River Valleys. While most infections are asymptomatic or self-limited, immunosuppressed patients may develop acute pulmonary infection or severe and progressive disseminated disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Who is at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of histoplasmosis is 5 percent for patients with AIDS who reside in endemic areas and who are not receiving antiretroviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/53\">",
"     53",
"    </a>",
"    ]. Disseminated disease is more common in patients with a CD4 count less than 150",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Preventing exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients visiting endemic areas should be advised to avoid high-risk activities, such as disturbing soil under bird roosting sites, demolishing old buildings, or exploring caves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    200 mg daily to placebo in 295 patients with HIV infection and CD4 cell counts below",
"    <span class=\"nowrap\">",
"     150/microL",
"    </span>",
"    showed a significant reduction in the incidence of histoplasmosis in the itraconazole group at a median follow-up of about one year (2.7 versus 6.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/56\">",
"     56",
"    </a>",
"    ]. However, a survival benefit was not demonstrated.",
"   </p>",
"   <p>",
"    The 2009",
"    <span class=\"nowrap\">",
"     NIH/CDC/IDSA",
"    </span>",
"    guidelines recommend consideration of prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for patients with a CD4 count below",
"    <span class=\"nowrap\">",
"     150/microL",
"    </span>",
"    who are at high risk because of occupational exposure or who live in a community with a hyperendemic rate of histoplasmosis (&gt;10",
"    <span class=\"nowrap\">",
"     cases/100",
"    </span>",
"    patient-years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylaxis can be discontinued when the CD4 count is",
"    <span class=\"nowrap\">",
"     &gt;150/mm3",
"    </span>",
"    for more than six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     CANDIDA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucosal candidal infections, such as oropharyngeal thrush and vaginitis, are commonly diagnosed in HIV-infected patients; invasive esophageal candidiasis is an AIDS-defining diagnosis that occurs in more than 10 percent of immunosuppressed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Preventing exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;These organisms are commonly found on skin and mucosal surfaces. No measures can be undertaken to reduce exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Who is at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The correlation between risk of mucosal disease and absolute CD4 cell count is not as clear as in other opportunistic infections. Recurrent candida vaginitis is the most common HIV-related gynecological presentation, but is also a common condition in women without HIV infection. Candida infections are also associated with antibiotic use, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    . The risk of candida esophagitis increases in patients with a CD4 count less than 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and in those with oropharyngeal thrush.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of primary prophylaxis have found efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    for the prevention of mucosal candidal infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/56,58,59\">",
"     56,58,59",
"    </a>",
"    ]. However, use of primary prophylaxis may also promote azole resistance in Candida species by selecting resistant strains (especially C. tropicalis, C. glabrata, and C. krusei) or by inducing resistance in the original strain of C. albicans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/60\">",
"     60",
"    </a>",
"    ]. The major risks for the induction of resistant strains are fluconazole exposure and severe immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, double-blind, multicenter study of 636 HIV-infected patients with median CD4 counts of 40",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      compared a once-weekly regimen of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (400 mg PO) to daily administration of fluconazole (200 mg PO) and found equivalent efficacy in the prevention of fungal infections (8 versus 6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/58\">",
"       58",
"      </a>",
"      ]. There was no placebo arm in the study. The daily regimen was more effective in preventing oral thrush. Once-weekly dosing did not appear to increase fluconazole resistance, but only a small subset of patients had sensitivity testing performed.",
"     </li>",
"     <li>",
"      In a prospective, double-blind trial, 295 patients with advanced HIV infection were randomized to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (200 mg daily) or placebo for prevention of mucosal and invasive fungal infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/56\">",
"       56",
"      </a>",
"      ]. Prophylaxis failure due to recurrent or refractory mucosal candidiasis occurred with similar frequency in patients receiving itraconazole or placebo (15 versus 16 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lingering concerns regarding the potential induction of resistance with the use of primary prophylaxis led to another randomized, open-label trial that compared oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    given 200 mg three times weekly (continuous use) with fluconazole that was provided only for episodes of oropharyngeal or esophageal candidiasis (episodic use) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/63\">",
"     63",
"    </a>",
"    ]. The primary endpoint was the time to development of fluconazole-refractory infection. A total of 829 patients were randomly assigned to the treatment arms. The study was significant for the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference in the clinical rates of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistance between the two arms.",
"     </li>",
"     <li>",
"      Continuous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      was associated with fewer cases of oropharyngeal and esophageal candidiasis and fewer invasive fungal infections, but not with improved survival, when compared to episodic treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that the use of continuous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    cannot be recommended due to the lack of a survival benefit, but could be considered in certain individuals with frequent mucosal infections or in non-Western settings where the rates of invasive fungal disease are much higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend the routine use of systemic prophylaxis for the primary prevention of candida infections despite studies showing effectiveness. The rationale for this recommendation is based on satisfactory response of mucosal candidiasis in AIDS patients and concerns of emerging drug resistance balanced against the effectiveness of therapy, the low associated mortality rate, and the cost of the drugs coupled with the risk of drug interactions. The alternative approach to systemic azoles for the treatment of oral thrush is the use of local antifungal therapy, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    troches or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    pastilles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     CRYPTOCOCCUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcosis most commonly presents as a meningoencephalitis with fever, malaise, and headache. The lifetime rate for AIDS patients in the pre-HAART era was 5 to 10 percent for cryptococcosis (90 percent have cryptococcal meningitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Preventing exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;No recommendations can be made regarding avoidance of exposure. There is no evidence that exposure to pigeon droppings increases the risk of cryptococcosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Who is at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of cases of cryptococcal infection occur in patients with a CD4 count &lt;50",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    benefits of primary prophylaxis for cryptococcal meningoencephalitis are unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. A systematic review identified five randomized controlled trials using antifungal interventions for the primary prevention of cryptococcal disease in a total of 1316 HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/66\">",
"     66",
"    </a>",
"    ]. The incidence of cryptococcal disease decreased significantly in patients taking either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ; however, there was no significant effect on mortality.",
"   </p>",
"   <p>",
"    We do not recommend the routine use of antifungal prophylaxis for primary prevention of cryptococcal infection because of the relative infrequency of cryptococcal disease, lack of survival benefits associated with prophylaxis, possibility of drug interactions, potential antifungal drug resistance, and cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that the experience may be different in resource-limited countries where cryptococcal meningitis is a common AIDS-defining complication and prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    has established benefit for preventing this complication with a significant reduction in mortality as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Fluconazole prophylaxis against cryptococcal infection has also been shown to reduce the incidence of esophageal and oropharyngeal candidiasis among Ugandan patients with advanced AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     COCCIDIOIDES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the development of combination antiretroviral therapy, coccidioidomycosis was recognized as a major opportunistic infection. While it is clear that coccidioidomycosis among HIV-infected patients can be due to reactivation of previously acquired infection, most cases identified within the coccidioidal endemic area appear to be due to recent acquisition.",
"   </p>",
"   <p>",
"    Persistently positive coccidioidal serological tests in HIV-infected patients appear to represent true coccidioidal infection and are associated with a significant risk of the development of active coccidioidomycosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/71\">",
"     71",
"    </a>",
"    ]. Prophylaxis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    is recommended for patients with a positive serology and a CD4 count",
"    <span class=\"nowrap\">",
"     &lt;250/mm3.",
"    </span>",
"   </p>",
"   <p>",
"    The most common clinical manifestation of coccidioidomycosis is pulmonary disease. Clinical expression is influenced by the state of immunosuppression; patients with relatively preserved CD4 counts have focal pneumonia while those with advanced immunosuppression present with diffuse infiltrates, indistinguishable from Pneumocystis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/72\">",
"     72",
"    </a>",
"    ]. Disseminated forms of coccidioidomycosis are common in the setting of HIV infection and include meningitis, and lymph node and skin involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21848?source=see_link\">",
"     \"Coccidioidomycosis in compromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Who is at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 602 AIDS patients with disseminated coccidioidomycosis, approximately 50 percent resided in endemic counties in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/74\">",
"     74",
"    </a>",
"    ]. However, the use of antiretroviral therapy appears to have decreased the incidence of symptomatic coccidioidomycosis in patients with AIDS living in endemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/75\">",
"     75",
"    </a>",
"    ]. The main risk factors for disease include a CD4 count &lt;250",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    a clinical diagnosis of AIDS, current or prior residence in an endemic area, and lack of HAART. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21848?source=see_link\">",
"     \"Coccidioidomycosis in compromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Preventing exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons living in endemic areas should avoid activities with increased risk, such as exposure to soil or excavation sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One retrospective case-controlled study in an endemic area suggested a decrease risk of coccidioidomycosis in those patients who had taken azole therapy for esophageal candidiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/75\">",
"     75",
"    </a>",
"    ]. The 2009",
"    <span class=\"nowrap\">",
"     NIH/CDC/HIV",
"    </span>",
"    Medicine Association Guidelines recommend either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    200 mg bid if the patient has a CD4 count",
"    <span class=\"nowrap\">",
"     &lt;250/mL,",
"    </span>",
"    positive IgG or IgM serology, and residence in an endemic area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If used, primary prophylaxis can be discontinued when CD4 counts are &ge;250",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     CYTOMEGALOVIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) infects multiple organ systems in late-stage HIV infection (CD4 count below",
"    <span class=\"nowrap\">",
"     50/microL).",
"    </span>",
"    The most frequent manifestation of CMV infection in this setting is a progressive retinitis, which occurred in 15 to 25 percent of patients in the pre-HAART era. However, the rate of CMV retinitis has decreased more than any other important OI during the era of potent ART.",
"   </p>",
"   <p>",
"    CMV may also cause esophagitis, colitis, enteritis, radiculitis, encephalitis, and hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22504?source=see_link\">",
"     \"AIDS-related cytomegalovirus gastrointestinal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7623?source=see_link\">",
"     \"AIDS-related cytomegalovirus neurologic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Who is at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk of CMV disease occurs mainly due to reactivation of latent infection in the setting of advanced immunosuppression, especially when CD4 counts are less than 50",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Preventing exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Past",
"    exposure to CMV infection is common in men who have sex with men and in injection drug users. If a patient is CMV seronegative, then advice should be given about potential routes of transmission (unprotected sexual intercourse, exposure to children with acute CMV infection). These patients should also receive CMV antibody negative blood transfusions or leukocyte-reduced cellular blood products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/55\">",
"     55",
"    </a>",
"    ]. Other methods to prevent transmission are the use of condoms and good hand-washing hygiene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prophylaxis with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    is effective in patients with a CD4 cell count &lt;50",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/55\">",
"     55",
"    </a>",
"    ]. A prospective study of oral ganciclovir (1000 mg TID) in persons with a CD4 count below",
"    <span class=\"nowrap\">",
"     50/microL",
"    </span>",
"    showed a significant reduction in CMV disease at 12 months (14 percent versus 26 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/76\">",
"     76",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/37/5718?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    has supplanted the use of ganciclovir due to greater potency and lower pill burden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, decisions regarding prophylaxis must take into account cost, the risk of developing CMV resistance, hematologic toxicity, the success of early therapy, and the lack of a proven survival benefit. In light of these issues,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    prophylaxis is not generally recommended.",
"   </p>",
"   <p>",
"    Patient education about the potential symptoms and signs of CMV retinitis is extremely important. Patients with low CD4 cell counts should be told to call their physicians immediately if they have symptoms of increased floaters, a field cut, or blurry vision. Regular funduscopic exams are recommended for AIDS patients with CD4 counts &lt;250",
"    <span class=\"nowrap\">",
"     cells/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     CRYPTOSPORIDIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptosporidiosis can cause severe watery diarrhea, electrolyte disturbance, and weight loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/40/13961?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Preventing exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of cryptosporidium can occur through contact with contaminated drinking water or food. HIV-infected patients should be advised to wash their hands after diaper changing, handling pets, and after contact with soil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/55\">",
"     55",
"    </a>",
"    ], or they should wear gloves. Vulnerable patients should also avoid eating raw oysters and should avoid oral-anal contact.",
"   </p>",
"   <p>",
"    Outbreaks, related to municipal water supplies, have led to severe diarrhea, biliary tract disease, and death in some patients with advanced immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Use of a submicron point-of-use water filter was demonstrated to be protective against acquisition of cryptosporidium infection in a \"look-back\" investigation of 400,000 cases in Milwaukee [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/80\">",
"     80",
"    </a>",
"    ]. During outbreaks, tap water should be boiled for three minutes before use. Commercial soft drinks are safe. Filters and bottled water are variable due to the lack of standards.",
"   </p>",
"   <p>",
"    Other preventative methods include refraining from drinking water from lakes or rivers, swimming in water with likely contamination, contact with stool from persons or animals, or eating raw oysters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no proven prophylactic regimens for cryptosporidium. However, studies of patients taking either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    for MAC prophylaxis demonstrated a protective effect against cryptosporidial infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study evaluated 1019 HIV-infected patients with a CD4 cell count below",
"      <span class=\"nowrap\">",
"       75/microL",
"      </span>",
"      from 10 HIV clinics in nine United States cities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/81\">",
"       81",
"      </a>",
"      ]. The relative hazard of cryptosporidiosis was 0.25 for patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      compared to those not treated with the drug (5 of 312 versus 30 of 707 patients) and 0.15 for patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      compared to those not treated with the drug (2 of 214 versus 33 of 805).",
"     </li>",
"     <li>",
"      However, no protective effect was seen in the 54 patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/81\">",
"       81",
"      </a>",
"      ], although azithromycin has been used in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"       paromomycin",
"      </a>",
"      to treat cryptosporidiosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/42/33450/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF WHEN TO INITIATE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures against opportunistic infections can include avoidance of certain exposures, good hygiene, and the use of prophylactic medications. Specific recommendations are governed by the degree of immunosuppression and the risk of disease, which varies for each pathogen.",
"   </p>",
"   <p>",
"    The need for primary prophylaxis is stratified below by CD4 cell count thresholds. Dosing recommendations and alternative therapies are found under each specific infection in \"Recommendations for individual pathogens\" below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h3\">",
"     CD4 counts &lt;200 cells/microL",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a CD4 count &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      are at risk for developing Pneumocystis infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    First line treatment options are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef53768 \" href=\"mobipreview.htm?12/40/12939\">",
"     table 2",
"    </a>",
"    ). For more detailed treatment recommendations (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Pneumocystis'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h3\">",
"     CD4 counts &lt;100 cells/microL",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a CD4 count &lt;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      are at risk for developing Pneumocystis infection.",
"     </li>",
"     <li>",
"      Patients who are Toxoplasma seropositive are also at risk for reactivation of toxoplasmosis infection.",
"     </li>",
"     <li>",
"      Patients who live in an endemic area for histoplasma are at risk for histoplasmosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    First line treatment options are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef53768 \" href=\"mobipreview.htm?12/40/12939\">",
"     table 2",
"    </a>",
"    ). For more detailed treatment recommendations (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Pneumocystis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Toxoplasma'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H62\">",
"     'Histoplasmosis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h3\">",
"     CD4 counts &lt;50 cells/microL",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a CD4 count &lt;50",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      are at risk for Pneumocystis and MAC infections.",
"     </li>",
"     <li>",
"      Patients who are Toxoplasma or CMV seropositive are also at risk for reactivation of these infections.",
"     </li>",
"     <li>",
"      Patients who live in an endemic area for histoplasma are at risk for histoplasmosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    First line treatment options are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef53768 \" href=\"mobipreview.htm?12/40/12939\">",
"     table 2",
"    </a>",
"    ). For more detailed treatment recommendations (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Pneumocystis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Toxoplasma'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H62\">",
"     'Histoplasmosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Mycobacterium avium complex'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Discontinuation of primary prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend discontinuation of primary prophylaxis for mycobacterium avium complex when the CD4 count is &gt;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      for 3 months (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend discontinuation of primary prophylaxis for Pneumocystis and toxoplasmosis when the CD4 count is &gt;200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      for 3 months (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR INDIVIDUAL PATHOGENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h2\">",
"     Pneumocystis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend TMP-SMX as first-line preventive therapy (one double strength tablet or one single strength tablet daily) in patients with a CD4 count less than 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      who do not have a history of allergy or severe reaction to sulfonamides or TMP-SMX (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In patients with severe reactions to TMP-SMX, we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      (100 mg given once daily) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pneumocystis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who cannot tolerate TMP-SMX or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      , we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      suspension (1500 mg daily with food) rather than aerosolized",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that during the first trimester, pregnant women be treated with aerosolized",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      rather than systemic prophylaxis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In the second and third trimester we recommend TMP-SMX as first line prophylaxis for Pneumocystis;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      is an alternative agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h2\">",
"     Toxoplasma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend TMP-SMX as first-line preventive therapy (one double strength tablet per day) in patients with a CD4 count &lt;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      who are toxoplasma seropositive (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Toxoplasma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have contraindications to TMP-SMX, we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      (200 mg orally per week) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      (75 mg orally per week) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      (25 mg orally per week) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In the patient who is intolerant or allergic to the above two regimens, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      (1500 mg once daily) with or without",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"        pyrimethamine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"        leucovorin",
"       </a>",
"       &nbsp;(",
"       <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"        Grade 2C",
"       </a>",
"       ).",
"      </span>",
"      Monotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      , pyrimethamine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      is not recommended.",
"     </li>",
"     <li>",
"      In pregnant women, we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      for the prophylaxis of toxoplasmosis starting in the second trimester (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"       Pyrimethamine",
"      </a>",
"      is teratogenic and should not be used during pregnancy.",
"     </li>",
"     <li>",
"      Patients who are seronegative for toxoplasma should be counseled to avoid eating undercooked meats (eg, lamb, beef, pork) and to use gloves when cleaning cat litter boxes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h2\">",
"     Mycobacterium avium complex",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend the use of macrolides rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      for the primary prophylaxis of MAC infection in patients with a CD4 count less than 50",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Given issues of dosing, drug interactions, and resistance, we suggest prophylaxis with weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      rather than daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Mycobacterium avium complex'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      is not tolerated,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      should be initiated. If neither macrolide is tolerated, then",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      can be considered an alternative. However, caution should be exercised when using either of these medications in light of known drug interactions with both clarithromycin and rifabutin. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Mycobacterium avium complex'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      may be used during pregnancy.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      is a teratogen in animals and should not be used during pregnancy. Experience with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      is limited.",
"     </li>",
"     <li>",
"      Before prophylaxis with macrolides is initiated, blood cultures for MAC isolation should be drawn if there is any suspicion of clinical disease. In patients initiating",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      , a chest x-ray should be obtained to rule out active tuberculosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h2\">",
"     Histoplasmosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (200 mg daily) for the prophylaxis of histoplasmosis in patients with a CD4 count &lt;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      who are at risk due to occupational exposure or who live in a community with a hyperendemic rate of histoplasmosis (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Histoplasma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h2\">",
"     Candida",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend NOT using systemic therapy for the primary prophylaxis for vaginal, oropharyngeal, or esophageal candidiasis due to concerns for resistance, cost, and potential for drug interactions (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Candida'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Azoles are teratogenic and should not be used during the first trimester of pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h2\">",
"     Cryptococcus",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that antifungal prophylaxis NOT be used routinely to prevent cryptococcosis because of the relative infrequency of cryptococcal disease, lack of survival benefits associated with prophylaxis, possibility of drug interactions, potential antifungal drug resistance, and cost (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Cryptococcus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Azoles are teratogenic and should not be used during pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65\">",
"    <span class=\"h2\">",
"     Coccidioidomycosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest administration of primary prophylaxis for coccidioidomycosis in patients with a CD4 count &lt;250",
"      <span class=\"nowrap\">",
"       cells/mL,",
"      </span>",
"      who have positive IgG or IgM serology, and who live or work in the endemic area. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66\">",
"    <span class=\"h2\">",
"     Cytomegalovirus",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk of CMV disease occurs mainly due to reactivation of latent infection in the setting of advanced immunosuppression, especially when CD4 counts are less than 50",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      However, we do NOT suggest routine prophylaxis due to cost, risk of resistance, and lack of proven survival benefit (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Cytomegalovirus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In seropositive patients with CD4 counts &lt;50 cells, we recommend three to six month ophthalmologic examinations for early detection of CMV retinitis (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). An equally important intervention is patient education about the symptoms of CMV retinitis, including floaters and blurry vision.",
"     </li>",
"     <li>",
"      For patients who are CMV seronegative, advice should be given about potential routes of transmission; additionally, they should receive CMV antibody negative blood transfusions or leukocyte-reduced cellular blood products when needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67\">",
"    <span class=\"h2\">",
"     Cryptosporidium",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest NOT administering prophylaxis for cryptosporidium (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H49\">",
"       'Cryptosporidium'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/41/26258?source=see_link\">",
"       \"Patient information: Hepatitis B (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36498?source=see_link\">",
"       \"Patient information: Vaccines for people with HIV (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/45/31447?source=see_link\">",
"       \"Patient information: Hepatitis B (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/1\">",
"      Freedberg KA, Scharfstein JA, Seage GR 3rd, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998; 279:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/2\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/3\">",
"      Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/4\">",
"      Brooks JT, Kaplan JE, Holmes KK, et al. HIV-associated opportunistic infections--going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis 2009; 48:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/5\">",
"      Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009; 48:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/6\">",
"      INSIGHT-ESPRIT Study Group, SILCAAT Scientific Committee, Abrams D, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/7\">",
"      Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/8\">",
"      Saah AJ, Hoover DR, Peng Y, et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study. JAMA 1995; 273:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/9\">",
"      Ioannidis JP, Cappelleri JC, Skolnik PR, et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996; 156:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/10\">",
"      Centers for Disease Control (CDC). Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1989; 38 Suppl 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/11\">",
"      Jones JL, Hanson DL, Dworkin MS, et al. Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996. J Infect Dis 1998; 178:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/12\">",
"      Dohn MN, White ML, Vigdorth EM, et al. Geographic clustering of Pneumocystis carinii pneumonia in patients with HIV infection. Am J Respir Crit Care Med 2000; 162:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/13\">",
"      Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/14\">",
"      Manoloff ES, Francioli P, Taff&eacute; P, et al. Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study. Emerg Infect Dis 2003; 9:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/15\">",
"      Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/16\">",
"      Castro G, Martinez R. Images in clinical medicine. Disseminated paracoccidioidomycosis and coinfection with HIV. N Engl J Med 2006; 355:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/17\">",
"      Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006; 367:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/18\">",
"      Lin D, Li WK, Rieder MJ. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst Rev 2007; :CD005646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/19\">",
"      Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis 1998; 27:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/20\">",
"      El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 1998; 339:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/21\">",
"      Chan C, Montaner J, Lefebvre EA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 1999; 180:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/22\">",
"      Hern&aacute;ndez-D&iacute;az S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/23\">",
"      Hern&aacute;ndez-D&iacute;az S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001; 153:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/24\">",
"      Trikalinos TA, Ioannidis JP. Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis. Clin Infect Dis 2001; 33:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/25\">",
"      Zellweger C, Opravil M, Bernasconi E, et al. Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study. AIDS 2004; 18:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/26\">",
"      Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001; 344:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/27\">",
"      Leport C, Ch&ecirc;ne G, Morlat P, et al. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. J Infect Dis 1996; 173:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/28\">",
"      Abgrall S, Rabaud C, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis 2001; 33:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/29\">",
"      Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med 1992; 327:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/30\">",
"      Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992; 327:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/31\">",
"      Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993; 7:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/32\">",
"      Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992; 117:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/33\">",
"      Girard PM, Landman R, Gaudebout C, et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. N Engl J Med 1993; 328:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/34\">",
"      Podzamczer D, Salazar A, Jim&eacute;nez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995; 122:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/35\">",
"      Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1995; 20:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/36\">",
"      Romand S, Pudney M, Derouin F. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother 1993; 37:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/37\">",
"      Kovacs JA. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Lancet 1992; 340:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/38\">",
"      Jacobson MA, Besch CL, Child C, et al. Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS. Lancet 1992; 339:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/39\">",
"      Furrer H, Opravil M, Bernasconi E, et al. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet 2000; 355:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/40\">",
"      Chin DP, Reingold AL, Stone EN, et al. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients--a prospective study. J Infect Dis 1994; 170:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/41\">",
"      Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/42\">",
"      Kuper JI, D'Aprile M. Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet 2000; 39:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/43\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/44\">",
"      Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/45\">",
"      Havlir DV, Dub&eacute; MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996; 335:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/46\">",
"      Oldfield EC 3rd, Fessel WJ, Dunne MW, et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis 1998; 26:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/47\">",
"      Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/48\">",
"      Benson CA, Williams PL, Cohn DL, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis 2000; 181:1289.",
"     </a>",
"    </li>",
"    <li>",
"     Sustiva [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2009.",
"    </li>",
"    <li>",
"     Viramune [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2008.",
"    </li>",
"    <li>",
"     Wise JE, Cozza KL. Infectious Diseases. In: Clinical manual of drug interaction principles for medical practice, Wynn GH (Ed), American Psychiatric Publishing Inc, Washington, DC 2009. p.257.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/52\">",
"      El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000; 342:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/53\">",
"      Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clin Infect Dis 2005; 40:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/54\">",
"      McKinsey DS, Spiegel RA, Hutwagner L, et al. Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology. Clin Infect Dis 1997; 24:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/55\">",
"      Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/56\">",
"      McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999; 28:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/57\">",
"      Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials 2000; 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/58\">",
"      Havlir DV, Dub&eacute; MP, McCutchan JA, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998; 27:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/59\">",
"      Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med 1997; 126:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/60\">",
"      Cameron ML, Schell WA, Bruch S, et al. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993; 37:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/61\">",
"      Revankar SG, Kirkpatrick WR, McAtee RK, et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 174:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/62\">",
"      Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/63\">",
"      Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 2005; 41:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/64\">",
"      Bozzette SA. Fluconazole prophylaxis in HIV disease, revisited. Clin Infect Dis 2005; 41:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/65\">",
"      Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989; 321:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/66\">",
"      Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev 2005; :CD004773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/67\">",
"      Singh N, Barnish MJ, Berman S, et al. Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of &lt; or = 100/mm3: demonstration of efficacy in a positive, multicenter trial. Clin Infect Dis 1996; 23:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/68\">",
"      Quagliarello VJ, Viscoli C, Horwitz RI. Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet 1995; 345:548.",
"     </a>",
"    </li>",
"    <li>",
"     Parkes-Ratanshi, R, Kamali, K, Wakeham, J, et al. Successful Primary Prevention of Cryptococcal Disease Using Fluconazole Prophylaxis in HIV-infected Ugandan Adults. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, February 8-11, 2009. Abstract 32.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/70\">",
"      Parkes-Ratanshi R, Wakeham K, Levin J, et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis 2011; 11:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/71\">",
"      Arguinchona HL, Ampel NM, Dols CL, et al. Persistent coccidioidal seropositivity without clinical evidence of active coccidioidomycosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 20:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/72\">",
"      Ampel NM. Coccidioidomycosis in persons infected with HIV type 1. Clin Infect Dis 2005; 41:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/73\">",
"      Fish DG, Ampel NM, Galgiani JN, et al. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore) 1990; 69:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/74\">",
"      Jones JL, Fleming PL, Ciesielski CA, et al. Coccidioidomycosis among persons with AIDS in the United States. J Infect Dis 1995; 171:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/75\">",
"      Woods CW, McRill C, Plikaytis BD, et al. Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: incidence, risk factors, and prevention. J Infect Dis 2000; 181:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/76\">",
"      Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 1996; 334:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/77\">",
"      Cvetkovi�� RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 2005; 65:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/78\">",
"      Mac Kenzie WR, Hoxie NJ, Proctor ME, et al. A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply. N Engl J Med 1994; 331:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/79\">",
"      Vakil NB, Schwartz SM, Buggy BP, et al. Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee. N Engl J Med 1996; 334:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/80\">",
"      Addiss DG, Pond RS, Remshak M, et al. Reduction of risk of watery diarrhea with point-of-use water filters during a massive outbreak of waterborne Cryptosporidium infection in Milwaukee, Wisconsin, 1993. Am J Trop Med Hyg 1996; 54:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/42/33450/abstract/81\">",
"      Holmberg SD, Moorman AC, Von Bargen JC, et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. JAMA 1998; 279:384.",
"     </a>",
"    </li>",
"    <li>",
"     Smith, NS. 5th Conference on Retroviruses, Feb 1-5, 1998; Chicago, Abstract 481.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3747 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33450=[""].join("\n");
var outline_f32_42_33450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY OF OPPORTUNISTIC INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESTORATION OF CELLULAR IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect of ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect of interleukin 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PNEUMOCYSTIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Who is at risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Preventing exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Discontinuation of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TOXOPLASMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Who is at risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Preventing exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Dapsone-pyrimethamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Atovaquone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Discontinuation of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MYCOBACTERIUM AVIUM COMPLEX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Who is at risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Preventing exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Rifabutin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Azithromycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Clarithromycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Evaluation prior to prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Discontinuation of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      HISTOPLASMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Who is at risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Preventing exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      CANDIDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Preventing exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Who is at risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      CRYPTOCOCCUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Preventing exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Who is at risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      COCCIDIOIDES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Who is at risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Preventing exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      CYTOMEGALOVIRUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Who is at risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Preventing exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      CRYPTOSPORIDIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Preventing exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      RECOMMENDATIONS OF WHEN TO INITIATE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      - CD4 counts &lt;200 cells/microL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      - CD4 counts &lt;100 cells/microL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      - CD4 counts &lt;50 cells/microL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Discontinuation of primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      RECOMMENDATIONS FOR INDIVIDUAL PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      Pneumocystis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      Toxoplasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      Mycobacterium avium complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      Histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      Candida",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      Cryptococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65\">",
"      Coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66\">",
"      Cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H67\">",
"      Cryptosporidium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3747\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3747|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/4/30795\" title=\"table 1\">",
"      Cost effectiveness OI Rx in HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/40/12939\" title=\"table 2\">",
"      OI prophylaxis in AIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/15/23804\" title=\"table 3\">",
"      PCP prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22504?source=related_link\">",
"      AIDS-related cytomegalovirus gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7623?source=related_link\">",
"      AIDS-related cytomegalovirus neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/8/12421?source=related_link\">",
"      Clarithromycin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21848?source=related_link\">",
"      Coccidioidomycosis in compromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9321?source=related_link\">",
"      Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/40/13961?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/8/3209?source=related_link\">",
"      HIV and malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38777?source=related_link\">",
"      Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37688?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36498?source=related_link\">",
"      Patient information: Vaccines for people with HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2889?source=related_link\">",
"      Prophylaxis against Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21546?source=related_link\">",
"      The global human immunodeficiency virus pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_42_33451="Physical findings in edema";
var content_f32_42_33451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major physical findings in edematous states",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pulmonary edema",
"       </td>",
"       <td class=\"subtitle1\">",
"        Central venous pressure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ascites and/or pedal edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left-sided heart failure",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right-sided heart failure",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cirrhosis",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &darr;-Normal",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal disease",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephrotic syndrome",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic edema",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &darr;-Normal",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Venous insufficiency",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        +, edema may be asymmetric",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33451=[""].join("\n");
var outline_f32_42_33451=null;
var title_f32_42_33452="Immune Rx systemic sclerosis";
var content_f32_42_33452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunosuppressive therapies for systemic sclerosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Selective immunosuppression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclosporine",
"       </td>",
"       <td>",
"        Inhibits T-helper cell actions by reducing IL-2 release, may reduce collagen synthesis",
"       </td>",
"       <td>",
"        Reported beneficial effects on skin sclerosis may be confounded by increased incidence of renal crisis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antithymocyte globulin",
"       </td>",
"       <td rowspan=\"2\">",
"        Temporary suppression of cell mediated immunity",
"       </td>",
"       <td rowspan=\"2\">",
"        Possible benefit for skin sclerosis although controlled trial of ATG confirms considerable therapy associated morbidity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antilymphocyte globulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CAMPATH-1H",
"       </td>",
"       <td>",
"        Lympholytic humanized monoclonal antibody",
"       </td>",
"       <td>",
"        Anecdotal benefit in case reports",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Photopheresis",
"       </td>",
"       <td>",
"        Extracorporeal photoactivated 8-methoxypsoralen inhibits activated T-cells",
"       </td>",
"       <td>",
"        Benefit has been reported but good placebo-controlled clinical trial is needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plasmapheresis",
"       </td>",
"       <td>",
"        Removes circulating immune mediators",
"       </td>",
"       <td>",
"        Equivocal results but anecdotal benefit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-CD20",
"       </td>",
"       <td>",
"        Depletion of B lymphocytes",
"       </td>",
"       <td>",
"        Little evidence for skin improvement; some cases suggest improvement of lung fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Nonselective immunosuppression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methotrexate",
"       </td>",
"       <td>",
"        Folic acid antagonist",
"       </td>",
"       <td>",
"        Two trials suggest potential benefit for skin disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        Alkylating agent",
"       </td>",
"       <td>",
"        Evidence of benefit for lung fibrosis in randomized trials and open-label studies; cyclophosphamide often combined with glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azathioprine",
"       </td>",
"       <td>",
"        Antimetabolite",
"       </td>",
"       <td>",
"        Anecdotal benefit reported in open studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autologous stem cell transplantation",
"       </td>",
"       <td>",
"        High dose immunosuppression (often with cyclophosphamide) followed by stem cell transplantation",
"       </td>",
"       <td>",
"        Limited evidence suggesting benefit for skin and on functional assessment; awaiting results from ongoing large randomized trials",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33452=[""].join("\n");
var outline_f32_42_33452=null;
var title_f32_42_33453="Stroke with carotid stenosis";
var content_f32_42_33453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Cause of stroke in patients with carotid stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 227px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this analysis of the NASCET cohort, the risk of a first ipsilateral stroke of cardioembolic, lacunar, or large-artery origin at five years after study entry is presented, according to the degree of asymptomatic carotid-artery stenosis. The risk of stroke was higher in patients with 60 to 99 percent stenosis compared to those with less than 60 percent stenosis in the asymptomatic carotid artery. However, approximately one-half of strokes were cardioembolic or lacunar in origin. The cause-specific risks are not additive; some patients had more than one stroke of more than one cause.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Inzitari, D, Eliasziw, M, Gates, P, et al, N Engl J Med 2000; 342:1693.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33453=[""].join("\n");
var outline_f32_42_33453=null;
var title_f32_42_33454="Contents: Antimicrobial drugs";
var content_f32_42_33454=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Antimicrobial drugs",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Antimicrobial drugs",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antibiotic resistance",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/56/26506\">",
"           Mechanisms of antibiotic resistance in enterococci",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/13/15575\">",
"           Microbiology of methicillin-resistant Staphylococcus aureus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/28/9672\">",
"           Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/5/81\">",
"           Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/18/3369\">",
"           Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/15/19704\">",
"           Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/16/23815\">",
"           Treatment of infections due to coagulase-negative staphylococci",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antibiotics &mdash; Aminoglycosides",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/34/24104\">",
"           Aminoglycosides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/30/8679\">",
"           Consolidated aminoglycoside dosing with gentamicin and tobramycin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/47/20215\">",
"           Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/41/18072\">",
"           Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antibiotics &mdash; Beta-lactams",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/46/23274\">",
"           Allergy to penicillins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/2/26663\">",
"           Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/33/9754\">",
"           Carbapenemases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/39/38519\">",
"           Cephalosporins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/47/44789\">",
"           Combination beta-lactamase inhibitors, carbapenems, and monobactams",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/5/1110\">",
"           Penicillins",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antibiotics &mdash; General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/53/30553\">",
"           Extended-spectrum beta-lactamases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/5/17495\">",
"           Overview of antibacterial susceptibility testing",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antibiotics &mdash; Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/30/1514\">",
"           Azithromycin, clarithromycin, and telithromycin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/39/23159\">",
"           Clindamycin: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/31/23031\">",
"           Colistin: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/4/31817\">",
"           Metronidazole: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/40/28298\">",
"           Pharmacology of antimicrobial agents for treatment of methicillin-resistant Staphylococcus aureus and vancomycin resistant enterococcus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/51/36662\">",
"           Tetracyclines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/34/38438\">",
"           Trimethoprim-sulfamethoxazole: An overview",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antibiotics &mdash; Quinolones",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/60/28618\">",
"           Fluoroquinolones",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antibiotics &mdash; Vancomycin",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/47/15096\">",
"           Vancomycin dosing and serum concentration monitoring in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/59/1978\">",
"           Vancomycin hypersensitivity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antifungals",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/21/29018\">",
"           Antifungal susceptibility testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/41/15001\">",
"           Pharmacology of amphotericin B",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/4/36938\">",
"           Pharmacology of azoles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/7/9338\">",
"           Pharmacology of echinocandins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/11/43190\">",
"           Pharmacology of flucytosine (5-FC)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antiparasitic drugs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/43/23221\">",
"           Anthelminthic therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/20/20809\">",
"           Antimalarial drugs: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/59/17335\">",
"           Antiprotozoal therapies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antiretrovirals",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/32/40458\">",
"           HIV protease inhibitors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antitubercular drugs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/2/30757\">",
"           Ethambutol: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/61/41943\">",
"           Isoniazid hepatotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/44/19142\">",
"           Isoniazid: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/62/34788\">",
"           Pyrazinamide: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/26/24998\">",
"           Rifampin and other rifamycins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/60/18375\">",
"           Second-line antituberculous therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antivirals (excluding drugs for HIV)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/60/10183\">",
"           Acyclovir: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/47/37620\">",
"           Cidofovir: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/10/6308\">",
"           Famciclovir: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/13/44244\">",
"           Foscarnet: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/25/17815\">",
"           Ganciclovir and valganciclovir: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/11/19640\">",
"           Pharmacology of antiviral drugs for influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/13/44249\">",
"           Prevention of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/46/22250\">",
"           Treatment of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/19/30003\">",
"           Valacyclovir: An overview",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-6A55549B18-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f32_42_33454=[""].join("\n");
var outline_f32_42_33454=null;
var title_f32_42_33455="Transverse vaginal septum";
var content_f32_42_33455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse vaginal septum with microperforation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_42_33455=[""].join("\n");
var outline_f32_42_33455=null;
